TY - JOUR AU - Boncz, Imre AU - Elmer, Diána AU - Németh, Noémi AU - Csákvári, Tímea AU - Ágoston, István AU - Kajos, Luca Fanni AU - SAÁGHY, ANDREA AU - KÁSÁDI, MÁRTA AU - Endrei, Dóra TI - Az egészségügyi szakdolgozók jövedelmének alakulása 2004-2021 között hazánkban JF - LEGE ARTIS MEDICINAE J2 - LEGE ART MED VL - 33 PY - 2023 IS - 10-11 SP - 523 EP - 531 PG - 9 SN - 0866-4811 DO - 10.33616/lam.33.0523 UR - https://m2.mtmt.hu/api/publication/34428240 ID - 34428240 N1 - University of Pécs, Faculty of Health Sciences, Institute of Health Insurance, Vörösmarty u. 3., Pécs, H-7621, Hungary University of Pécs, National Laboratory of Human Reproduction, Pécs, Hungary University of Pécs, Clinical Centre, Pécs, Hungary Export Date: 14 December 2023 CODEN: LAMEF Correspondence Address: Imre, B.; University of Pécs, Vörösmarty u. 3., Hungary; email: imre.boncz@etk.pte.hu LA - Hungarian DB - MTMT ER - TY - JOUR AU - Csákvári, Tímea AU - Elmer, Diána AU - Németh, Noémi AU - Kívés, Zsuzsanna AU - Horváth, Lilla Anita AU - Wittmann, István AU - Boncz, Imre TI - A 2-es típusú diabetes mellitus és szövődményei epidemiológiai és betegségteher-vizsgálata rutinszerűen gyűjtött egészségbiztosítási adatok alapján JF - DIABETOLOGIA HUNGARICA J2 - DIABETOLOGIA HUNGARICA VL - 31 PY - 2023 IS - 1 SP - 17 EP - 25 PG - 9 SN - 1217-372X DO - 10.24121/dh.2023.2 UR - https://m2.mtmt.hu/api/publication/33750477 ID - 33750477 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Dubey, A.K. AU - Chabert, G.L. AU - Carriero, A. AU - Pasche, A. AU - Danna, P.S.C. AU - Agarwal, S. AU - Mohanty, L. AU - Nillmani, A AU - Sharma, N. AU - Yadav, S. AU - Jain, A. AU - Kumar, A. AU - Kalra, M.K. AU - Sobel, D.W. AU - Laird, J.R. AU - Singh, I.M. AU - Singh, N. AU - Tsoulfas, G. AU - Fouda, M.M. AU - Alizad, A. AU - Kitas, G.D. AU - Khanna, N.N. AU - Viskovic, K. AU - Kukuljan, M. AU - Al-Maini, M. AU - El-Baz, A. AU - Saba, L. AU - Suri, J.S. TI - Ensemble Deep Learning Derived from Transfer Learning for Classification of COVID-19 Patients on Hybrid Deep-Learning-Based Lung Segmentation: A Data Augmentation and Balancing Framework JF - DIAGNOSTICS J2 - DIAGNOSTICS VL - 13 PY - 2023 IS - 11 SN - 2075-4418 DO - 10.3390/diagnostics13111954 UR - https://m2.mtmt.hu/api/publication/34064774 ID - 34064774 N1 - Bharati Vidyapeeth’s College of Engineering, New Delhi, 110063, India Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.), Cagliari, 09123, Italy Department of Radiology, “Maggiore della Carità” Hospital, University of Piemonte Orientale, Via Solaroli 17, Novara, 28100, Italy Advanced Knowledge Engineering Centre, GBTI, Roseville, CA 95661, United States ABES Engineering College, Ghaziabad, 201009, India Department of Computer Science Engineering, Bennett University, Greater Noida, 201310, India School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, 221005, India Department of Radiology, Massachusetts General Hospital, Boston, MA 02115, United States Men’s Health Centre, Miriam Hospital Providence, Providence, RI 02906, United States Heart and Vascular Institute, Adventist Health St. Helena, St. Helena, CA 94574, United States Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA 95661, United States Department of Food Science and Technology, Graphic Era, Deemed to be University, Dehradun, 248002, India Department of Surgery, Aristoteleion University of Thessaloniki, Thessaloniki, 54124, Greece Department of Electrical and Computer Engineering, Idaho State University, Pocatello, ID 83209, United States Department of Physiology & Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, United States Academic Affairs, Dudley Group NHS Foundation Trust, Dudley, DY1 2HQ, United Kingdom Department of Cardiology, Indraprastha APOLLO Hospitals, New Delhi, 110001, India Department of Radiology and Ultrasound, University Hospital for Infectious Diseases, Zagreb, 10000, Croatia Department of Interventional and Diagnostic Radiology, Clinical Hospital Center Rijeka, Rijeka, 51000, Croatia Allergy, Clinical Immunology & Rheumatology Institute, Toronto, ON L4Z 4C4, Canada Biomedical Engineering Department, University of Louisville, Louisville, KY 40292, United States Export Date: 17 July 2023 Correspondence Address: Suri, J.S.; Stroke Monitoring and Diagnostic Division, United States; email: jasjit.suri@atheropoint.com AB - Background and motivation: Lung computed tomography (CT) techniques are high-resolution and are well adopted in the intensive care unit (ICU) for COVID-19 disease control classification. Most artificial intelligence (AI) systems do not undergo generalization and are typically overfitted. Such trained AI systems are not practical for clinical settings and therefore do not give accurate results when executed on unseen data sets. We hypothesize that ensemble deep learning (EDL) is superior to deep transfer learning (TL) in both non-augmented and augmented frameworks. Methodology: The system consists of a cascade of quality control, ResNet–UNet-based hybrid deep learning for lung segmentation, and seven models using TL-based classification followed by five types of EDL’s. To prove our hypothesis, five different kinds of data combinations (DC) were designed using a combination of two multicenter cohorts—Croatia (80 COVID) and Italy (72 COVID and 30 controls)—leading to 12,000 CT slices. As part of generalization, the system was tested on unseen data and statistically tested for reliability/stability. Results: Using the K5 (80:20) cross-validation protocol on the balanced and augmented dataset, the five DC datasets improved TL mean accuracy by 3.32%, 6.56%, 12.96%, 47.1%, and 2.78%, respectively. The five EDL systems showed improvements in accuracy of 2.12%, 5.78%, 6.72%, 32.05%, and 2.40%, thus validating our hypothesis. All statistical tests proved positive for reliability and stability. Conclusion: EDL showed superior performance to TL systems for both (a) unbalanced and unaugmented and (b) balanced and augmented datasets for both (i) seen and (ii) unseen paradigms, validating both our hypotheses. © 2023 by the authors. LA - English DB - MTMT ER - TY - JOUR AU - Elmer, Diána AU - Boncz, Imre AU - Németh, Noémi AU - Csákvári, Tímea AU - Kajos, Luca Fanni AU - Kívés, Zsuzsanna AU - Ágoston, István AU - Endrei, Dóra TI - Az orvosok fizetésének alakulása 1998 és 2021 között hazánkban JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 29 SP - 1146 EP - 1154 PG - 9 SN - 0030-6002 DO - 10.1556/650.2023.32810 UR - https://m2.mtmt.hu/api/publication/34073777 ID - 34073777 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Horváth, Lilla Anita AU - Boncz, Imre AU - Kívés, Zsuzsanna AU - Fehér, Gergely AU - Németh, Noémi AU - Kajos, Luca Fanni AU - Biró, Katalin AU - Fendrik, Krisztina AU - Koltai, Katalin AU - Késmárky, Gábor AU - Endrei, Dóra TI - Disease-Specific Quality of Life among Patients with Peripheral Artery Disease in Hungary JF - INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH J2 - INT J ENV RES PUB HE VL - 20 PY - 2023 IS - 4 PG - 14 SN - 1661-7827 DO - 10.3390/ijerph20043558 UR - https://m2.mtmt.hu/api/publication/33647023 ID - 33647023 AB - Peripheral artery disease (PAD) is a progressive atherosclerotic disease significantly impacting functional status and health-related quality of life (HRQoL). This study aimed to investigate HRQoL among PAD patients in Hungary using the validated Hungarian version of the PADQoL questionnaire. Patients with symptomatic PAD were consecutively recruited from the Department of Angiology, Clinical Center, University of Pécs, Hungary. Demographics, risk factors, and comorbidities were registered. Disease severity was measured by Fontaine and WIFI stages. Descriptive statistical analysis, Chi-square test, and non-parametric tests were performed (p < 0.05). Overall, 129 patients (mean age 67.6 ± 11.9 years, men 51.9%) participated in our study. The Hungarian PADQoL demonstrated good internal consistency (α range: 0.745–0.910). Factors on intimate and social relationships gave the best (89.15 ± 20.91; 63.17 ± 26.05) and sexual function (28.64 ± 27.42), and limitations in physical functioning (24.68 ± 11.40) the worst scores. PAD had a significant negative impact on the social relationships of patients aged 21–54 years (51.6 ± 25.4). Fontaine stage IV patients experienced significantly lower HRQoL due to fear and uncertainty (46.3 ± 20.9) and limited physical functioning (33.2 ± 24.8). The Hungarian PADQoL identified central aspects of HRQoL. Advanced PAD was found to impact several areas of HRQoL, primarily physical functioning and psycho-social well-being, drawing attention to the importance of early diagnosis and management. LA - English DB - MTMT ER - TY - JOUR AU - McQueen, R. Brett AU - Mendola, Nicholas D. AU - Jakab, Ivett AU - Bennett, Jeffrey AU - Nair, Kavita V AU - Németh, Bertalan AU - Inotai, András AU - Kaló, Zoltán TI - Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods JF - PHARMACOECONOMICS-OPEN J2 - PHARMACOECON-OPEN VL - 7 PY - 2023 IS - 2 SP - 217 EP - 228 PG - 12 SN - 2509-4262 DO - 10.1007/s41669-022-00376-w UR - https://m2.mtmt.hu/api/publication/33236361 ID - 33236361 N1 - Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States Syreon Research Institute, Budapest, Hungary School of Medicine, Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary Export Date: 6 July 2023 Correspondence Address: McQueen, R.B.; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E. Montview Blvd., United States; email: robert.mcqueen@cuanschutz.edu AB - Background and Objective Several novel methods have been suggested to extend a conventional value assessment to capture a more comprehensive perspective of value from a patient perspective. The objective of this research was to demonstrate a framework for implementing a combined qualitative and quantitative method to elicit and prioritize patient experience value elements in rare diseases. Neuromyelitis optica spectrum disorder was used as a case study.Methods The method for eliciting and prioritizing patient experience value elements involved a three-step process: (1) collecting potential patient experience value elements from existing literature sources followed by deliberation by a multi-stakeholder research team; (2) a pre-workshop webinar and survey to identify additional patient-reported value elements; and (3) a workshop to discuss, prioritize the value elements using a swing weighting method. Outcomes were prioritized value elements with normalized weights for patients considering a treatment for neuromyelitis optica spectrum disorder.Results A literature review and deliberation resulted in the following initial value elements: ability to reach important personal milestones, patient's financial burden, value of hope/balance or timing of risks and benefits, Uncertainty about long-term benefits and safety of the treatment, Patient empowerment through therapeutic advancement and technology, Caregiver/family's financial burden, patient experience related to treatment regimen, Therapeutic options, and Caregiver/ family's quality of life. Eight patients with neuromyelitis optica spectrum disorder participated in the case study. In the online survey, participants found the nine proposed patient experience value elements both understandable and important with no additions. During the workshop, 'Uncertainty about long-term benefits and safety,' 'Patient experience related to treatment regimen,' and 'Patient's financial burden' were found to be the most important patient experience value elements, with a respective weight of 25%, 19.2%, and 14.4% (out of total 100%).Conclusions This case study provides a framework for eliciting and prioritizing patient experience value elements using direct patient input. Although elements/weights may differ by disease, and even in neuromyelitis optica spectrum disorder, additional research is needed, value frameworks, researchers, and manufacturers can use this practical method to generate patient experience value elements and evaluate their impact on treatment selection. LA - English DB - MTMT ER - TY - JOUR AU - Répásy, Balázs AU - Gazsó, Gyula Tibor AU - Elmer, Diána AU - Pónusz-Kovács, Dalma AU - Kajos, Luca Fanni AU - Csákvári, Tímea AU - Kovács, B. AU - Boncz, Imre TI - The long-term effect of generic price competition on the Hungarian statin market JF - BMC HEALTH SERVICES RESEARCH J2 - BMC HEALTH SERV RES VL - 23 PY - 2023 IS - 1 PG - 8 SN - 1472-6963 DO - 10.1186/s12913-023-09431-6 UR - https://m2.mtmt.hu/api/publication/33862409 ID - 33862409 N1 - Faculty of Health Sciences, Institute for Health Insurance, University of Pécs, Vörösmarty U. 3, Pécs, 7621, Hungary National Laboratory for Human Reproduction, Ifjúság Útja 20, Pécs, 7624, Hungary Export Date: 24 May 2023 Correspondence Address: Boncz, I.; Faculty of Health Sciences, Vörösmarty U. 3, Hungary; email: imre.boncz@etk.pte.hu AB - Background: Generic competition is a vital health policy tool used in regulating the pharmaceutical market. Drug group HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase) inhibitors, widely known as “statins,” was the first drug group in Hungary in which generic prescriptions became mandatory. Our aim is to analyze the changes in the retail and wholesale margins through the generic competition regarding “statins”. Methods: Data was derived from the nationwide pharmaceutical database of the Hungarian National Health Insurance Fund Administration, the only health care financing agency in Hungary. We observed the turnover data regarding the HMG-CoA-reductase inhibitor “statins” from 2010 through 2019. As the drugs under review have a fixed price point in Hungary, we effectively calculated the margins. Results: In 2010, the consumer expenditure of statins was 30.7 billion HUF ($148 million), which decreased by 59%, to 12.5 billion HUF ($42.9 million) in 2019. In 2010, the annual health insurance reimbursement of statins was 23.7 billion HUF ($114 million), which underwent a 63% decrease to 8.6 billion HUF ($29.7 million) in 2019. In 2010, the DOT turnover was 287 million days, and it increased to above 346 million days for 2019, which reflects a 20% increase over the past nine years. The monthly retail margins decreased from 334 million HUF ($1.6 million), (January, 2010) to 176 million HUF ($0.61 million), (December, 2019). The monthly wholesale margins decreased from 96.3 million HUF ($0.46 million), (January, 2010) to 41.4 million HUF ($0.14 million), (December, 2019). The most significant downturn in margins was due to the introduction of the first two blind bids. The combined DOT turnover in reference to the examined 43 products consistently increased. Conclusions: The decline in retail and wholesale margin and in health insurance expenditures was largely due to a reduction in the consumer price of generic medicines. DOT turnover of statins also increased significantly. © 2023, The Author(s). LA - English DB - MTMT ER - TY - JOUR AU - Elmer, Diána AU - Endrei, Dóra AU - Németh, Noémi AU - Csákvári, Tímea AU - Kajos, Luca Fanni AU - Molics, Bálint AU - Boncz, Imre TI - Az egészségügyi szakdolgozók létszámváltozása az európai egészségügyi rendszerekben 2000 és 2018 között JF - ORVOSI HETILAP J2 - ORV HETIL VL - 163 PY - 2022 IS - 41 SP - 1639 EP - 1648 PG - 10 SN - 0030-6002 DO - 10.1556/650.2022.32580 UR - https://m2.mtmt.hu/api/publication/33110422 ID - 33110422 AB - Introduction: Ensuring the supply of healthcare professionals is an important health policy issue nowadays.Objective: The aim of our research is to provide a comprehensive picture of the health workforce situation in the European OECD countries.Data and methods: Indicators analyzed regarding the numbers of practising midwives, nurses, physiotherapists and total hospital beds were derived from the "OECD Health Statistics 2021" database for the period 2000-2018. 24 European OECD countries were grouped according to the type of healthcare system and geographical location. Data were subsequently compared by parametric and nonparametric tests, focusing especially on years 2000, 2010, 2018. Results: Between 2000 and 2018, there was a 14% increase in the average number of midwives, a 30% increase in the average number of nurses, and a 41% increase in the average number of physiotherapists per 100,000 population in the OECD countries examined. Per 100 hospital beds, the average number of midwives increased by 72%, the num-ber of nurses by 86%, and the number of physiotherapists by 97%. Significant results for all three years analyzed were obtained in the number of physiotherapists per 100 hospital beds (p = 0.014; p<0.001; p = 0.002) when comparing the Western and Eastern European countries examined. As for the healthcare systems, significant results were ob-tained only in the number of nurses per 100 hospital beds for the year 2010 (p = 0.048).Conclusion: Among healthcare professional groups, the number of physiotherapists increased the most in Europe. The numbers of healthcare professionals per 100 beds are significantly higher in Western European countries ana-lyzed compared to Eastern European countries. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Elmer, Diána AU - Endrei, Dóra AU - Németh, Noémi AU - Horváth, Lilla Anita AU - Pónusz, Róbert AU - Kívés, Zsuzsanna AU - Danku, Nóra AU - Csákvári, Tímea AU - Ágoston, István AU - Boncz, Imre TI - Changes in the Number of Physicians and Hospital Bed Capacity in Europe JF - VALUE IN HEALTH REGIONAL ISSUES J2 - VAL HEALTH REG ISS VL - 32 PY - 2022 SP - 102 EP - 108 PG - 7 SN - 2212-1099 DO - 10.1016/j.vhri.2022.07.003 UR - https://m2.mtmt.hu/api/publication/33115790 ID - 33115790 LA - English DB - MTMT ER - TY - JOUR AU - Kajos, Luca Fanni AU - Molics, Bálint AU - Than, Péter AU - Gőbel, Gy AU - Boncz, Imre TI - Csípőízületi protézisműtéten átesett betegek szociodemográfiai jellemzőinek és rövid távú életminőségének vizsgálata JF - ORVOSI HETILAP J2 - ORV HETIL VL - 163 PY - 2022 IS - 26 SP - 1037 EP - 1046 PG - 10 SN - 0030-6002 DO - 10.1556/650.2022.32499 UR - https://m2.mtmt.hu/api/publication/32912767 ID - 32912767 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Pónusz, Róbert AU - Endrei, Dóra AU - Kovács, D AU - Boncz, Imre TI - Az egynapos sebészet teljesítményvolumenének vizsgálata az aktív fekvőbeteg-ellátás tükrében JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 13 PY - 2022 IS - 3-4 SP - 71 EP - 81 PG - 11 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/34138553 ID - 34138553 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Pónusz, Róbert AU - Boncz, Imre AU - Pónusz-Kovács, Dalma AU - Csonka, Diána AU - Gazsó, Tibor AU - Molics, Bálint AU - Ludman, István AU - Endrei, Dóra TI - A magyarországi várólista-csökkentési program orvosszakmai összetételének, igénybevételi mutatóinak és területi megoszlásának elemzése 2015–2018 időszakában JF - LEGE ARTIS MEDICINAE J2 - LEGE ART MED VL - 32 PY - 2022 IS - 3 SP - 121 EP - 131 PG - 11 SN - 0866-4811 DO - 10.33616/lam.32.011 UR - https://m2.mtmt.hu/api/publication/32780128 ID - 32780128 AB - BEVEZETÉS – Magyarországon 2015-tôl kezdôdôen szisztematikus várólista-csökkentési program vette kezdetét („ X” térítési kategória) a várakozási idô számottevô mérséklése céljából. Vizsgálatunkban a 2015–2018 közötti idôszakban az „ X” térítési kategóriában elszámolt esetek igénybevételi mutatóit és területi megoszlását elemeztük. MÓDSZEREK – Retrospektív, kvantitatív kutatásunk a Nemzeti Egészségbiztosítási Alapkezelô által biztosított adatbázison alapult, amely a várólista-csökkentési program finanszírozására 2015-ben létrehozott „ X” térítési kategóriában elszámolt esetszámokat foglalta magában 2015–2018 között. Az adatbázis tartalmazta a betegek nemét és életkorát, megye szerinti lakhelyét, az ellátó intézmény megyéjének és típusának megnevezését, valamint az elvégzett beavatkozásokat. EREDMÉNYEK – A vizsgálati idôszakban 27 716 esetszámot (átlagéletkor 68,05 év) számoltak el nôi többséggel (63,1%). Tízezer lakosra vetítve, az esetszám az alábbi megyékben volt a legmagasabb: Baranya (84,63), Somogy (60,17) és Zala (58,89). Az elszámolt eseteket 71,6%-ban a beteg lakóhelye szerinti megye határán belül látták el. A legnagyobb számban szürkehályogmûtéteket finanszíroztak. KÖVETKEZTETÉSEK – A várólista-csökkentési programban elszámolt esetek között jelentôs területi egyenlôtlenségeket találtunk. Az intézményi szerepvállalás is változatos képet mutatott. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Varga, Veronika AU - Sélleyné Gyuró, Monika AU - Juhász, Rebeka AU - Koczka, Viktor AU - Szőts, Bálint AU - Molics, Bálint AU - Boncz, Imre TI - Patient Satisfaction Survey in Hospitals Providing SPA Care in Hungary JF - STUDIA UNIVERSITATIS BABES-BOLYAI EDUCATIO ARTIS GYMNASTICAE J2 - STUD UNIV BABES-BOLYAI EDUCATIO ARTIS GYMNASTICAE VL - 67 PY - 2022 IS - 1 SP - 5 EP - 18 PG - 14 SN - 1453-4223 DO - 10.24193/subbeag.67(1).01 UR - https://m2.mtmt.hu/api/publication/32848670 ID - 32848670 LA - English DB - MTMT ER - TY - JOUR AU - Csákvári, Tímea AU - Elmer, Diána AU - Németh, Noémi AU - Kívés, Zsuzsanna AU - Wittmann, István AU - Janszky, József Vladimír AU - Boncz, Imre TI - A diabeteses polyneuropathia okozta epidemiológiai és egészségbiztosítási betegségteher elemzése egészségbiztosítási adatok alapján = Assessing the epidemiological disease burden and health insurance treatment cost of diabetic polyneuropathy based on health insurance claims data JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 38 EP - 45 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32156 UR - https://m2.mtmt.hu/api/publication/31936543 ID - 31936543 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Elmer, Diána AU - Endrei, Dóra AU - Sebestyén, Andor AU - Csákvári, Tímea AU - Németh, Noémi AU - Horváth, Lilla Anita AU - Pónusz, Róbert AU - Kumánovics, Gábor AU - Boncz, Imre AU - Ágoston, István TI - A rheumatoid arthritis okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon = Nationwide epidemiological and health insurance disease burden of rheumatoid arthritis in Hungary JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 30 EP - 37 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32157 UR - https://m2.mtmt.hu/api/publication/31936723 ID - 31936723 N1 - Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Pécs, Hungary Pécsi Tudományegyetem, Egészségtudományi Kar, Real World and Big Data Egészség-gazdaságtani Kutatókozpont, Pécs, Hungary Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Zalaegerszeg, Hungary Pécsi Tudományegyetem, Általános Orvostudományi Kar, Klinikai Kozpont, Reumatológiai és Immunológiai Klinika, Pécs, Hungary Export Date: 30 January 2024; Cited By: 2; Correspondence Address: D. Elmer; Pécs, Vörösmarty u. 3, 7621, Hungary; email: diana.elmer@etk.pte.hu; CODEN: ORHEA LA - Hungarian DB - MTMT ER - TY - JOUR AU - Elmer, Diána AU - Csákvári, Tímea AU - Horváth, Lilla Anita AU - Boncz, Imre TI - Comment on Gerner T. et al. JF - PEDIATRIC ALLERGY AND IMMUNOLOGY J2 - PEDIATR ALLERGY IMMU VL - 32 PY - 2021 IS - 7 SP - 1585 EP - 1587 PG - 3 SN - 0905-6157 DO - 10.1111/pai.13546 UR - https://m2.mtmt.hu/api/publication/32073877 ID - 32073877 LA - English DB - MTMT ER - TY - JOUR AU - Gazsó, Gyula Tibor AU - Elmer, Diána AU - Endrei, Dóra AU - Sebestyén, Andor AU - Kajos, Luca Fanni AU - Wiegand, Norbert AU - Boncz, Imre TI - A pertrochanter törés okozta éves epidemiológiai és egészségbiztosítási betegségteher elemzése Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 46 EP - 53 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32162 UR - https://m2.mtmt.hu/api/publication/31936601 ID - 31936601 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kaló, Zoltán AU - Petykó, Zsuzsanna AU - Fricke, Frank-Ulrich AU - Maniadakis, Nikos AU - Tesar, Tomas AU - Podrazilova, Katerina AU - Espin, Jaime AU - Inotai, András TI - Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives JF - Cost Effectiveness and Resource Allocation J2 - COST EFFECT RESOUR A VL - 19 PY - 2021 IS - 1 PG - 8 SN - 1478-7547 DO - 10.1186/s12962-021-00296-2 UR - https://m2.mtmt.hu/api/publication/32127830 ID - 32127830 AB - Background A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes across countries and to create incentives for manufacturers to invest into incremental innovation. However, this can be impactful only if the framework can be adapted to heterogeneous health care financing systems in different jurisdictions, and the cost of evidence generation necessitated by the framework takes into account the anticipated benefits for the health care system and rewards for the developers. Areas covered The framework could potentially improve the pricing and reimbursement decisions of VAMs by adapting it to different country specific decision-contexts such as deliberative processes, augmented cost-effectiveness frameworks or formal multi-criteria decision analysis (MCDA); alternatively, some of its domains may be added to current general evaluation frameworks of medicines. The proposed evaluation framework may provide a starting point for practices based on which VAMs can be exempted from generic pricing mechanisms or can be integrated into the reimbursement and procurement system, allowing for price differentiation according to their added value. Besides evidence from RCTs, pricing and reimbursement decision processes of VAMs should allow for ex-ante non-RCT evidence for certain domains. Alternatively, relying on ex-post evidence agreements-such as outcome guarantee or coverage with evidence development-can also reduce decision uncertainty. Conclusions The core evaluation framework for VAMs could trigger changes in the existing pricing, reimbursement and procurement practices by improving the appraisal of the added value created by incremental innovation. LA - English DB - MTMT ER - TY - JOUR AU - Kívés, Zsuzsanna AU - Endrei, Dóra AU - Elmer, Diána AU - Csákvári, Tímea AU - Kajos, Luca Fanni AU - Boncz, Imre AU - Mangel, László Csaba AU - Vajda, Réka TI - A vastag- és végbéldaganat okozta országos epidemiológiai és egészségbiztosítási betegteher Magyarországon = Epidemiological disease burden and annual health insurance treatment cost of colorectal cancer in Hungary JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 14 EP - 21 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32152 UR - https://m2.mtmt.hu/api/publication/31908948 ID - 31908948 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Vajda, Réka AU - Boncz, Imre AU - Elmer, Diána AU - Csákvári, Tímea AU - Németh, Noémi AU - Kajos, Luca Fanni AU - Pónusz-Kovács, Dalma AU - Bódis, József AU - Kívés, Zsuzsanna TI - A méhnyakrák okozta éves epidemiológiai és egészségbiztosítási betegségteher Magyarországon = Annual epidemiological and health insurance burden of cervical cancer in Hungary JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 22 EP - 29 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32158 UR - https://m2.mtmt.hu/api/publication/31936765 ID - 31936765 AB - Összefoglaló. Bevezetés: A méhnyakdaganatok kérdése kiemelten fontos, megoldatlan népegészségügyi probléma. A betegség terhe magas, ami elsősorban az alacsony és közepes jövedelmű országokban élőknél jelentkezik. Célkitűzés: Elemzésünk célja volt meghatározni a méhnyakdaganatok epidemiológiai és egészségbiztosítási betegségterhét Magyarországon a 2018-as évre vonatkoztatva. Adatok és módszerek: Elemzésünket a Nemzeti Egészségbiztosítási Alapkezelő (NEAK) finanszírozási adatbázisának 2018. évi adatai alapján végeztük az in situ (D06), a jóindulatú (D26.0) és a malignus (C53) méhnyakdaganatokra vonatkozóan. Az elemzés a NEAK által finanszírozott összes szolgáltatóra és ellátási formára kiterjed. Meghatároztuk az éves betegszámokat, a prevalenciát 100 000 lakosra, továbbá az éves egészségbiztosítási kiadásokat betegségcsoportonként és korcsoportos bontásban, valamennyi egészségbiztosítási ellátás tekintetében. Eredmények: A NEAK 2018-ban 1,276 milliárd Ft-ot (4,7 millió USD; 4,0 millió EUR) költött a méhnyakdaganatok kezelésére. A betegek és a finanszírozás döntő többsége a méhnyak rosszindulatú daganatához kapcsolható. A finanszírozásból a malignus méhnyakdaganatok részesedése 97%. Ellátási típusonként vizsgálva a legnagyobb kiadási tétel az aktívfekvőbeteg-szakellátásban jelenik meg, éves szinten 763,9 millió Ft, ami az összköltség 59,9%-a. A 100 000 lakosra jutó prevalencia az aktívfekvőbeteg-szakellátás igénybevételi adatai alapján 26/100 000 lakos. Következtetés: A méhnyakdaganatok kezelésének meghatározó költségeleme az aktívfekvőbeteg-szakellátás. Hazánkban a szervezett méhnyakszűrés korszerűsítéseként az új szűrési stratégiát megfelelő finanszírozási támogatással célszerű bevezetni, a szűrővizsgálatoknak, a hozzájuk kapcsolódó további diagnosztikus kivizsgálásnak és terápiának a teljesítményvolumen-korlát alóli mentesítésével. Orv Hetil. 2021; 162(Suppl 1): 22-29.Cervical cancer is a particularly important, unresolved public health problem. The burden of the disease is high, primarily in those living in low- and middle-income countries.Our aim was to determine the annual epidemiological disease burden and health insurance cost of cervical cancer in Hungary in 2018.Our analysis was made according to the financial database of the National Health Insurance Fund Administration (NHIFA) of Hungary for the year 2018, which covers all service providers and maintenance forms financed by NHIFA. We analysed the in situ (D06), the benignant (D26.0) and the malignant (C53) cervical tumours. The data analysed included annual patient numbers and prevalence of care utilisation per 100 000 population furthermore annual health insurance costs calculated for disease and age groups.In 2018, NHIFA spent 1.276 billion HUF (4.7 million USD, 4.0 million EUR) on the treatment of patients with cervical cancer. The majority of patients and funding can be linked to malignant cervical cancer (97%). Acute inpatient care was the major cost driver: 763.9 million HUF (59.9% of the total health insurance expenditures) annually. The prevalence is 26 per 100 000 population based on acute inpatient care data.Acute inpatient care was the major cost driver. In Hungary, as a modernization of organized cervical screening, it is appropriate to introduce a new screening strategy with appropriate financial support, by exempting screening tests, associated additional diagnostic testing, and therapy from the performance volume limit. Orv Hetil. 2021; 162(Suppl 1): 22-29. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Németh, Noémi AU - Endrei, Dóra AU - Horváth, Lilla Anita AU - Elmer, Diána AU - Csákvári, Tímea AU - Pónusz, Róbert AU - Szapáry, László AU - Boncz, Imre TI - A cerebrovascularis betegségekből eredő, idő előtti halálozás egyenlőtlenségei Európában 1990 és 2014 között = Inequalities in premature mortality due to cerebrovascular disease in Europe between 1990 and 2014 JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - 4 SP - 144 EP - 152 PG - 9 SN - 0030-6002 DO - 10.1556/650.2021.31980 UR - https://m2.mtmt.hu/api/publication/31828627 ID - 31828627 AB - Összefoglaló. Bevezetés: A cerebrovascularis betegségek népegészségügyi szempontból jelentősek, világszerte a vezető halálokok között szerepelnek, és a rokkantság egyik fő okát képezik. Célkitűzés: Vizsgálatunk célja a cerebrovascularis betegségekből eredő, idő előtti halálozás hazai és nemzetközi adatainak elemzése régiónkénti bontásban a 45-59 éves korcsoportban. Módszerek: Retrospektív, kvantitatív elemzés keretében vizsgáltuk a cerebrovascularis betegségekből eredő, korspecifikus, 1990 és 2014 közötti halálozást az Egészségügyi Világszervezet (WHO) Európai Régióján belül kiválasztott nyugat-európai (n = 17), kelet-európai országokban (n = 10) és a volt Szovjetunió utódállamaiban (n = 15), 100 000 főre vetítve, a WHO Európai Halálozási Adatbázisának adatai alapján. Leíró statisztikai módszereket, idősoros kimutatást, Kruskal-Wallis-próbát alkalmaztunk. Eredmények: A cerebrovascularis betegségekből eredő, 100 000 főre vetített korspecifikus halálozás a nyugat-európai országokban volt a legalacsonyabb (férfiak: 1990: 35,14, 2014: 14,31; nők: 1990: 21,11, 2014: 8,76) és a Szovjetunió utódállamaiban a legmagasabb (férfiak: 1990: 134,19; 2014: 91,13; nők: 1990: 83,62, 2014: 41,83) (p<0,05). A kelet-európai és a nyugat-európai országok, valamint a nyugat-európai országok és a Szovjetunió utódállamainak korspecifikus, cerebrovascularis halálozása között szignifikáns különbséget találtunk mindkét nemben (1990, 2004, 2014: p<0,05). A cerebrovascularis betegségek korspecifikus standardizált halálozása 1990 és 2014 között a nyugat-európai országokban (férfiak: -59,28%, nők: -58,29%) csökkent a legnagyobb mértékben, melyet a vizsgált kelet-európai országok (férfiak: -54,14%, nők: -57,53%), majd a Szovjetunió utódállamai (férfiak: -32,09%, nők: -49,97%) követtek. Következtetések: A korspecifikus, cerebrovascularis halálozás a férfiak és a nők körében egyaránt csökkent az egyes régiókban. Magyarországon a nyugat-európai átlagnál jobban, 62,2%-kal csökkent a férfiak és 59,1%-kal a nők korai cerebrovascularis halálozása 1990 és 2014 között. Orv Hetil. 2021; 162(4): 144-152.Cerebrovascular diseases are a significant public health concern, they are among the leading causes of death worldwide and one of the major causes of disability.Our aim was to analyse national and international data regarding premature, cerebrovascular disease mortality per region in the 45-59 age group.We performed a retrospective, quantitative analysis on age-specific, premature cerebrovascular disease mortality between 1990 and 2014 per 100 000 population on data derived from the World Health Organisation, European Mortality Database on Western European (n = 17), Eastern European (n = 10) countries, and countries of the former Soviet Union (n = 15). Descriptive statistics, time series analysis and Kruskal-Wallis test were performed.Age-related, cerebrovascular disease mortality per 100 000 population was the lowest in Western European countries (males: 1990: 35.14, 2014: 14.31; females: 1990: 21.11, 2014: 8.76), and the highest in former Soviet Union countries (males: 1990: 134.19; 2014: 91.13; females: 1990: 83.62, 2014: 41.83) (p<0,05). Significant differences were found in age-specific, cerebrovascular disease mortality in both sexes between Eastern and Western European countries and former Soviet Union countries (1990, 2004, 2014: p<0.05). Between 1990 and 2014, age-specific, standardized cerebrovascular disease mortality showed the biggest decrease in Western European countries (males: -59.28%, females: -58.29%) followed by Eastern European (males: -54.14%, females: -57.53%) and former Soviet Union countries (males: -32.09%, females: -49.97%).Age-specific, cerebrovascular disease mortality decreased in both sexes in all regions analysed. Hungary was found to have seen a decrease above the Western European average, premature cerebrovascular mortality decreased by 62.2% in males and 59.1% in females between 1990 and 2014. Orv Hetil. 2021; 162(4): 144-152. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Németh, Noémi AU - Endrei, Dóra AU - Elmer, Diána AU - Csákvári, Tímea AU - Horváth, Lilla Anita AU - Kajos, Luca Fanni AU - Cziráki, Attila AU - Boncz, Imre TI - A heveny szívinfarktus okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon = Epidemiological disease burden and annual health insurance treatment cost of acute myocardial infarction in Hungary JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 6 EP - 13 PG - 8 SN - 0030-6002 DO - 10.1556/650.2021.32153 UR - https://m2.mtmt.hu/api/publication/31936763 ID - 31936763 AB - Összefoglaló. Bevezetés: A szív- és érrendszeri betegségek a vezető halálokok között szerepelnek világszerte, az összes halálozás egyharmadáért, míg az európai halálozások közel feléért felelősek. Célkitűzés: Vizsgálatunk célja volt a heveny szívinfarktus okozta epidemiológiai és egészségbiztosítási betegségteher elemzése. Adatok és módszerek: Adataink a Nemzeti Egészségbiztosítási Alapkezelő (NEAK) finanszírozási adatbázisából származnak a 2018-as évre vonatkozóan. Meghatároztuk az éves betegszámokat és a legnagyobb kiadással rendelkező ellátási forma, az aktívfekvőbeteg-szakellátás tekintetében a 100 000 főre jutó prevalenciát, valamint az éves egészségbiztosítási kiadásokat korcsoportos és nemenkénti bontásban az egyes ellátási típusokra vonatkozóan. A heveny szívinfarktust a Betegségek Nemzetközi Osztályozásának 10. revíziója alapján az I21-es kódcsoporttal azonosítottuk. Eredmények: A NEAK heveny szívinfarktusra fordított kiadása összesen 16,728 milliárd Ft (61,902 millió USD; 52,463 millió EUR) volt 2018-ban. A teljes kiadás 95,8%-át az aktívfekvőbeteg-szakellátás költségei (16,032 milliárd Ft; 59,321 millió USD; 50,276 millió EUR) képezték; ezen ellátási forma keretén belül összesen 16 361 fő (9742 férfi és 6619 nő) került kórházi felvételre. A valamennyi életkorra számított, 100 000 lakosra vetített prevalencia 208,54 beteg volt a férfiak és 129,61 beteg a nők esetében az aktívfekvőbeteg-szakellátásban. A nemenkénti eloszlást tekintve az aktívfekvőbeteg-szakellátásban a férfiak abszolút száma - a 75 év felettiek kivételével - valamennyi vizsgált korcsoportban meghaladta a nőkét. Következtetés: Az aktívfekvőbeteg-szakellátás igénybevétele bizonyult a legfőbb költségtényezőnek. Orv Hetil. 2021; 162(Suppl 1): 6-13.Cardiovascular diseases have been the leading causes of death worldwide accounting for one third of all-cause mortality, and nearly half of mortality in Europe.The aim of our study was to determine the epidemiological disease burden of acute myocardial infarction.Data were derived from the financial database of the National Health Insurance Fund Administration (NHIFA) of Hungary for 2018. Data analysed included annual patient numbers, prevalence per 100 000 population in acute inpatient care, health insurance costs calculated for age groups and sex for all types of care. Patients with acute myocardial infarction were identified with the code: I21 of the International Classification of Diseases, 10th revision.In 2018, NHIFA spent 16.728 billion HUF on the treatment of acute myocardial infarction, 61.902 million USD, 52.463 million EUR. Acute inpatient care accounted for 95.8% of costs (16.032 billion HUF; 59.321 million USD; 50.276 million EUR) with 16 361 persons (9742 male; 6619 females) hospitalised. Based on patient numbers in acute in-patient care, prevalence per 100 000 among men was 208.54, among women 129.61 patients. In all age groups, except for patients aged >75 years, the number of males was higher than that of females.Acute inpatient care was the major cost driver in the treatment of acute myocardial infarction. Orv Hetil. 2021; 162(Suppl 1): 6-13. LA - Hungarian DB - MTMT ER - TY - BOOK ED - Renee, J. G. Arnold TI - Pharmacoeconomics From Theory to Practice PB - CRC Press - Taylor and Francis Group CY - Boca Raton, Florida PY - 2021 SN - 9780367521363 UR - https://m2.mtmt.hu/api/publication/32337715 ID - 32337715 LA - English DB - MTMT ER - TY - JOUR AU - Varga, Veronika AU - Elmer, Diána AU - Boncz, Imre AU - Sipos, Dávid AU - Kajos, Luca Fanni AU - Sebestyén, Andor AU - Molics, Bálint TI - A térd- és lábszársérülések okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon = The nationwide epidemiological and health insurance disease burden of knee and lower leg injuries in Hungary JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - Suppl 1 SP - 54 EP - 60 PG - 7 SN - 0030-6002 DO - 10.1556/650.2021.32160 UR - https://m2.mtmt.hu/api/publication/31937550 ID - 31937550 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Zelei, Tamas AU - Mendola, Nicholas D. AU - Elezbawy, Baher AU - Nemeth, Bertalan AU - Campbell, Jonathan D. TI - Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review JF - PHARMACOECONOMICS-OPEN J2 - PHARMACOECON-OPEN VL - 5 PY - 2021 IS - 4 SP - 605 EP - 612 PG - 8 SN - 2509-4262 DO - 10.1007/s41669-021-00271-w UR - https://m2.mtmt.hu/api/publication/32053727 ID - 32053727 N1 - Funding Agency and Grant Number: PhRMA Foundation Center of Excellence Grant; University of Colorado School of Medicine Funding text: This research was supported by a PhRMA Foundation Center of Excellence Grant, for Pharmaceutical Value (pValue), alongside matching financial support from Data Science to Patient Value from the University of Colorado School of Medicine. AB - Background Traditionally, the economic value of health technologies is assessed with cost-effectiveness (CE) and budget impact (BI) analyses. However, the evaluation of rare disease therapies often considers novel value criteria. Multi-criteria decision analysis (MCDA) is a promising tool in the assessment of value criteria that typically cannot be captured with traditional approaches. Objectives The objective of this research was to investigate the criteria and scoring functions applied in value frameworks and MCDA tools relevant to the evaluation of rare disease therapies. The aim was to gain a better understanding of the domains and measurement of commonly referenced novel value criteria. Methods A systematic literature review was performed covering the period from 2013 to 2019. MCDA or value framework articles and structured review papers on orphan-drug-specific MCDA articles were reviewed. Information sources included MEDLINE, Embase, Scopus, and 26 other gray literature sources. A descriptive review of identified criteria and scoring functions was performed, with special focus on "novel" value criteria that are traditionally not considered in CE or BI analyses. Results In total, 15 relevant value frameworks and MCDA tools were identified. These studies included a large number (n = 56) of individual value criteria. The most commonly included novel criteria were unmet medical need, severity of disease, and reduction in uncertainty. The identified scoring functions (measurement methods) for novel criteria were highly heterogeneous and tailored. Standardized scoring functions were not observed. Additionally, the studies did not provide their rationale for choosing a specific scoring function for a criterion. Conclusions MCDA is a promising tool to include novel value criteria into the health technology assessment of therapies for rare diseases. To support the development of a transparent and justified evaluation process, scoring functions should be further investigated. LA - English DB - MTMT ER - TY - JOUR AU - Babashov, Vusal AU - Ben Amor, Sarah AU - Reinhardt, Gilles TI - Framework for Drug Formulary Decision Using Multiple-Criteria Decision Analysis JF - MEDICAL DECISION MAKING J2 - MED DECIS MAKING VL - 40 PY - 2020 IS - 4 SP - 438 EP - 447 PG - 10 SN - 0272-989X DO - 10.1177/0272989X20915241 UR - https://m2.mtmt.hu/api/publication/31462218 ID - 31462218 N1 - Cited By :3 Export Date: 9 May 2023 CODEN: MDMAD Correspondence Address: Reinhardt, G.; Telfer School of Management, Canada; email: gilles.reinhardt@telfer.uottawa.ca AB - Background. Reviewing drugs to determine coverage or reimbursement level is a complex process that involves significant time and expertise. Review boards gather evidence from the submission provided, input from clinicians and patients, and results of clinical and economic reviews. This information consists of assessments on multiple criteria that often conflict with one another. Multiple-criteria decision analysis (MCDA) includes methods to address complex decision making problems with conflicting objectives and criteria. We propose an MCDA approach that infers a utility model based on reviews of previously submitted drugs. Methods. We use a recent extension of the UTilities Additives DIScriminantes approach, UTADIS(GMS). This disaggregation approach deconstructs a portfolio of elements such as a set of drugs that have been reviewed and for which a decision has been made. It derives global and marginal utility functions that are consistent with the preferences exhibited by the review boards in their recommendations. We apply the method to oncology drugs reviewed in Canada between 2011 and 2017. We also illustrate how to conduct scenario analyses and predict the coverage decisions for new drugs. Results. Applying the method yields a utility value for each submission along with a set of thresholds that partition the utility values based on the submission outcomes. Scenario analyses illustrate the predictive ability of the method. Conclusion. Preference disaggregation is an indirect way of eliciting an additive global utility value function. It requires less of a cognitive effort from the decision making bodies because it infers preferences from the data rather than relying on direct assessments of model parameters. We illustrate how it can be applied to validate existing decisions and to predict the recommendation of a new drug. LA - English DB - MTMT ER - TY - JOUR AU - Boncz, Imre AU - Sebestyén, Andor AU - Endrei, Dóra AU - Ágoston, István AU - Csákvári, Tímea AU - Kovács, L. Gábor AU - Miseta, Attila János TI - A közfinanszírozott laboratóriumi szolgáltatások egészségpolitikai tapasztalatai Magyarországon egészségbiztosítási adatok elemzésével JF - ORVOSI HETILAP J2 - ORV HETIL VL - 161 PY - 2020 IS - 12 SP - 468 EP - 473 PG - 6 SN - 0030-6002 DO - 10.1556/650.2020.31683 UR - https://m2.mtmt.hu/api/publication/31252046 ID - 31252046 AB - Introduction: In order to provide appropriate prevention, diagnosztics, decision on therapy and monitoring the results of medical treatment, there is an increasing need for laboratory examinations. Aim: The aim of our study is the health-ecnomics analysis of laboratory budget of the Hungarian Health Insurance Fund. Data and method: Data were derived from the financial database of the National Health Insurance Fund Administration. The analysis covered the period of 2002-2018. We analysed the annual budget for laboratory examinations, the number of patients and examinations, the market share of laboratory services providers according to their owner structure from the health insurance curative-preventive budget. Results: The budget available for financing the laboratory examinations (21-22 billion Hungarian forint (Ft)/év) did not change significantly between 2005 and 2015. There was a significant decrease in the number of both patients and examinations between 2006 and 2008. In the latest years, there were 14-15 million cases per year and 180 million examinations per year. The market share of for-profit companies decreased from 29.0% in 2010 to 10.6% in 2018, while the market share of governmental institutions increased from 27.1% in 2010 to 78.7% in 2018. Conclusion: The activity of laboratories was stabilized in the latest years. After the necessary correction of professional regulations and code maintenance, the laboratory budget can be increased towards the mainly public laboratory services providers. Orv Hetil. 2020; 161(12): 468-473. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Czech, M. AU - Baran-Kooiker, A. AU - Atikeler, K. AU - Demirtshyan, M. AU - Gaitova, K. AU - Holownia-Voloskova, M. AU - Turcu-Stiolica, A. AU - Kooiker, C. AU - Piniazhko, O. AU - Konstandyan, N. AU - Zalis'ka, O. AU - Sykut-Cegielska, J. TI - A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries JF - FRONTIERS IN PUBLIC HEALTH J2 - FRONT PUBLIC HEALTH VL - 7 PY - 2020 SN - 2296-2565 DO - 10.3389/fpubh.2019.00416 UR - https://m2.mtmt.hu/api/publication/31296936 ID - 31296936 N1 - Department of Pharmacoeconomics, The Institute of Mother and Child, Warsaw, Poland Department of Pharmacoeconomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands Unit of Health Technology Assessments, Turkish Ministry of Health, Turkish Medicines and Medical Devices Agency, Ankara, Turkey Ascent Global Market Solutions (Non-profit), Walnut Creek, CA, United States Center for Economics and Health Technology Assessment, Republican Center for Health Development, Ministry of Health, Nur-Sultan, Kazakhstan State Budgetary Institution Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow, Russian Federation Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland Department of Pharmacoeconomics, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania Independent Researcher, Warsaw, Poland Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine Republican Center of Medical Genetics, Yerevan State Medical University, Yerevan, Armenia Department of Inborn Errors of Metabolism and Paediatrics, The Institute of Mother and Child, Warsaw, Poland Cited By :52 Export Date: 9 May 2023 Correspondence Address: Baran-Kooiker, A.; Department of Pharmacoeconomics, Poland; email: aleksandra.baran@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Csákvári, Tímea AU - Sebestyén, Andor AU - Elmer, Diána AU - Németh, Noémi AU - Pónusz, Róbert AU - Komáromy, Márk AU - Zemplényi, Antal Tamás AU - Endrei, Dóra AU - Boncz, Imre TI - Az Egészségbiztosítási Alap bevételi és kiadási oldalának elemzése 1993-2019 között JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 11 PY - 2020 IS - 1-2 SP - 5 EP - 18 PG - 14 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/32012764 ID - 32012764 LA - Hungarian DB - MTMT ER - TY - JOUR AU - DiStefano, Michael J. AU - Krubiner, Carleigh B. TI - Beyond the numbers: a critique of quantitative multi-criteria decision analysis JF - INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE J2 - INT J TECHNOL ASSESS VL - 36 PY - 2020 IS - 4 SP - 292 EP - 296 PG - 5 SN - 0266-4623 DO - 10.1017/S0266462320000410 UR - https://m2.mtmt.hu/api/publication/31722210 ID - 31722210 N1 - Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, United States Center for Global Development, Washington, DC, United States Cited By :10 Export Date: 9 May 2023 CODEN: IJTCE Correspondence Address: Distefano, M.J.; Berman Institute of Bioethics, 1809 Ashland Ave., United States; email: mdistef1@jhu.edu AB - When setting priorities for health, there is broad agreement that a range of social values and ethical principles beyond clinical and cost-effectiveness matter, but exactly how health technology assessment (HTA) should account for a broader set of criteria remains an area of ongoing debate. In light of this, we welcome a recent review paper by Baltussen et al. evaluating the potential of different multi-criteria decision analysis (MCDA) approaches to enable HTA agencies to incorporate a broader set of values in their appraisals. The authors describe three approaches to MCDA-qualitative MCDA, quantitative MCDA, and MCDA with decision rules-laying out their relative advantages and disadvantages and providing recommendations for how they can best be implemented. While we endorse many of the authors' assessments and conclusions, including the critical role of deliberation in any MCDA approach and the undertaking of qualitative MCDA at a minimum, we take a stronger position regarding the flaws of quantitative MCDA and strongly caution against it. We find quantitative MCDA antithetical to at least two of the ways MCDA is intended to improve HTA recommendations: (i) enhancing quality and (ii) promoting transparency. Quantitative MCDA may mask the complex tradeoffs that exist within and between decision criteria and remain generally inaccessible to those who are not well-versed in its technical methods of appraisal. We advocate for a predominantly qualitative approach to MCDA appraisal centered around deliberation and supplemented with decision aids to help account for health opportunity costs. LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Lilla Anita AU - Boncz, Imre AU - Kívés, Zsuzsanna AU - Németh, Noémi AU - Biró, Katalin AU - Fendrik, Krisztina AU - Koltai, Katalin AU - Késmárky, Gábor AU - Endrei, Dóra TI - A perifériás verőérbetegek életminőségét vizsgáló angol nyelvű kérdőív magyar adaptálása JF - ORVOSI HETILAP J2 - ORV HETIL VL - 161 PY - 2020 IS - 51 SP - 2153 EP - 2161 PG - 9 SN - 0030-6002 DO - 10.1556/650.2020.31920 UR - https://m2.mtmt.hu/api/publication/31787979 ID - 31787979 AB - Összefoglaló. Bevezetés: A perifériás verőérbetegség napjaink egyik világméretű népegészségügyi problémája, több mint 200 millió embert érint világszerte. A Peripheral Artery Disease Quality of Life (PADQOL) kérdőívet azzal a céllal fejlesztették ki, hogy a betegség fizikai tünetein kívül annak szubjektív betegségterhét, pszichoszociális és emocionális hatásait is vizsgálja. Célkitűzés: Az eredeti, angol nyelvű PADQOL betegségspecifikus, önkitöltős kérdőív magyar nyelvű, érvényes változatának kifejlesztése, annak fordítása, kultúrközi adaptációja és magyar nyelvi validálása. Módszerek: Az életminőség-kérdőív lingvisztikai validálása nemzetközi protokoll alapján történt: két szakfordító külön-külön lefordította a kérdőívet angol forrásnyelvről magyarra; egy harmadik szakfordító bevonásával elkészült a két verzió szintézise, majd azt két, angol anyanyelvű fordító visszafordította angol forrásnyelvre, amit konszenzusmegbeszélés követett. A "pre-final" magyar verzió érthetőségét 30, angiológiai járó és fekvő beteg bevonásával, kognitív interjúk lefolytatásával, pilotvizsgálat során teszteltük. A PADQOL kérdőív faktorstruktúrájának feltárásához faktoranalízist végeztünk, az alskálák megbízhatóságát, a tételek belső konzisztenciáját a Cronbach-alfa-együttható kiszámításával vizsgáltuk. Az elemzésekhez IBM SPSS 23.0 programcsomagot használtunk. Eredmények: A PADQOL nyelvi validálása jelentéstani, tapasztalati és idiomatikus ekvivalencia tekintetében nem jelentett nehézséget. A kognitív interjúk során egy kérdés esetén tapasztaltunk értelmezési nehézséget. A kérdőív "pre-final" verziója tartalmilag és nyelvileg könnyen érthető, kitöltése nem okoz nehézséget. Az egyes dimenziók Cronbach-α-értéke 0,624 és 0,887 között volt. A legrosszabb értéket a Félelem és bizonytalanság (score-átlag: 14,07) életminőség-dimenzió mutatta. Következtetés: Létrehoztuk a PADQOL kérdőív végső magyar verzióját, mely mérőeszköz alkalmas a nyelvi és kultúrközi adaptáció következő lépésének elvégzésére, nagyobb betegpopuláción történő pszichometriai és klinikometriai vizsgálat által a perifériás verőérbetegek életminőségének, szubjektív betegségterhének felmérését célzó validálásra. Orv Hetil. 2020; 161(51): 2153-2161.Peripheral artery disease is one of the greatest, global public health concerns affecting more than 200 million people worldwide. The Peripheral Artery Disease Quality of Life questionnaire was developed to assess the subjective disease burden of peripheral artery disease, by focusing on psychosocial and emotional effects besides physical symptoms and functional limitations.To develop the valid Hungarian version of the original PADQOL via the standard linguistic validation and cross-cultural adaptation procedure.The linguistic validation was conducted according to an international protocol: two independent forward translations, a synthesis of the translations, back translations and consensus team review. The pilot-testing of the 'pre-final' Hungarian version was conducted via cognitive interviews with 30 in- and outpatients attending the Department of Angiology. Factor analysis was performed, Cronbach-alpha values were calculated to establish the reliability of subscales and to determine the internal consistency if items. IBM SPSS 23.0 was used.The linguistic validation of PADQOL into Hungarian posed no difficulties in terms of semantic, experiential and idiomatic equivalence. One item was found difficult to interpret during cognitive interviewing. The 'pre-final' version of the questionnaire was easy to understand and complete. Cronbach-alpha values of factors ranged between 0.624 and 0.887. The lowest value was that of factor 4: Fear and Uncertainty (mean score: 14.07).The linguistic validation of PADQOL into Hungarian was successful, the final Hungarian version is a tool that should reveal valuable insights with regard to subjective disease burden of patients living with peripheral artery disease subsequent to psychometric and clinicometric validation on a larger patient population. Orv Hetil. 2020; 161(51): 2153-2161. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Jakab, Ivett AU - Németh, Bertalan AU - Elezbawy, Baher AU - Karadayı, Melis Almula AU - Tozan, Hakan AU - Aydın, Sabahattin AU - Shen, Jie AU - Kaló, Zoltán TI - Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries—A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 11 PY - 2020 PG - 12 SN - 1663-9812 DO - 10.3389/fphar.2020.01203 UR - https://m2.mtmt.hu/api/publication/31403083 ID - 31403083 N1 - Syreon Research Institute, Budapest, Hungary Syreon Middle East, Alexandria, Egypt İstanbul Medipol University, İstanbul, Turkey Novartis International AG, Basel, Switzerland Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary Cited By :6 Export Date: 17 July 2023 Correspondence Address: Jakab, I.; Syreon Research InstituteHungary LA - English DB - MTMT ER - TY - JOUR AU - Schleierné, Rónaszéki J AU - Lóth, E AU - Gazsó, Gyula Tibor AU - Kívés, Zsuzsanna AU - Endrei, Dóra TI - A krónikus fekvőbeteg szakellátás helyzetelemzése országos, megyei és intézményi adatok alapján JF - NŐVÉR J2 - NŐVÉR VL - 33 PY - 2020 IS - 6 SP - 33 EP - 38 PG - 6 SN - 0864-7003 UR - https://m2.mtmt.hu/api/publication/31806550 ID - 31806550 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Boncz, Imre AU - Kovács, Gábor TI - Az Egészségbiztosítási Alap munkaerőpiaci kapcsolódásai Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 ET - 0 PY - 2019 IS - Suppl.1 SP - 3 EP - 5 PG - 3 SN - 0030-6002 DO - 10.1556/650.2019.31410 UR - https://m2.mtmt.hu/api/publication/30429843 ID - 30429843 N1 - Export Date: 13 September 2019 CODEN: ORHEA Correspondence Address: Imre, B.; Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási IntézetHungary; email: imre.boncz@etk.pte.hu LA - Hungarian DB - MTMT ER - TY - JOUR AU - Boncz, Imre AU - Sebestyén, Andor AU - Csákvári, Tímea AU - Ágoston, István AU - Szabados, Eszter AU - Endrei, Dóra TI - A kardiológiai rehabilitáció teljesítménymutatói Magyarországon [Performance indicators of cardiac rehabilitation in Hungary] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 ET - 0 PY - 2019 IS - Suppl. 1 SP - 6 EP - 12 PG - 7 SN - 0030-6002 DO - 10.1556/650.2019.31370 UR - https://m2.mtmt.hu/api/publication/30425673 ID - 30425673 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Boncz, Imre AU - Endrei, Dóra AU - Csákvári, Tímea AU - Ágoston, István AU - Cserháti, Péter AU - Molics, Bálint AU - Sebestyén, Andor TI - A neuromusculoskeletalis rehabilitáció szakmapolitikai indikátorai Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 ET - 0 PY - 2019 IS - Suppl. 1 SP - 13 EP - 21 PG - 9 SN - 0030-6002 DO - 10.1556/650.2019.31371 UR - https://m2.mtmt.hu/api/publication/30425707 ID - 30425707 AB - Introduction: With the increasing number of the incidence of neuromusculoskeletal and brain circulation disorders, there is a higher demand for neuromusculoskeletal rehabilitation care.Aims: The aim of our study is to analyse the performance indicators of neuromusculoskeletal rehabilitation care in Hungary financed by the statutory public health insurance system.Methods: Data were derived from the financial database of the National Health Insurance Fund of Hungary. We analysed the period between 2014 and 2017. We investigated the distribution of neuromusculoskeletal rehabilitation hospital beds, the patient turnover and patients' pathways. We analysed the regional inequalities in the access to (hospital beds) and utilization (number of patients) of rehabilitation care.Results: In 2017, there were 6798 publicly financed neuromusculoskeletal rehabilitation hospital beds in Hungary (6.94 beds/10 000 population). We observed the lowest number of hospital bed in Komarom-Esztergom (1.5 beds/10 000 population), Somogy (2.0) and Pest (2.7) counties. We found the highest number of hospital beds in Zala (12.6), Gyor-Moson-Sopron (12.2) and Baranya (11.5) counties. The more than 2-fold difference in the utilization (Komarom-Esztergom: 52.3 patients/10 000 population; Gyor-Moson-Sopron: 136 patients/10 000 population) confirms regional inequalities. Between 2014 and 2017, the annual number of patients showed an increasing tendency, while the average length of stay varied between 21.8 and 22.4 days/patient. The correlation coefficient between hospitals beds and the number of patients was very high (0.798).Conclusion: We found significant regional inequalities in the access to and utilization of neuromusculoskeletal rehabilitation. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Csanádi, Marcell AU - Loblova, Olga AU - Ozieranski, Piotr AU - Harsányi, András AU - Kaló, Zoltán AU - Mckee, Martin AU - King, Lawrence TI - When health technology assessment is confidential and experts have no power: the case of Hungary JF - HEALTH ECONOMICS, POLICY AND LAW J2 - HEALTH ECON POL LAW VL - 14 PY - 2019 IS - 2 SP - 162 EP - 181 PG - 20 SN - 1744-1331 DO - 10.1017/S1744133118000051 UR - https://m2.mtmt.hu/api/publication/30585158 ID - 30585158 N1 - Cited By :14 Export Date: 23 January 2022 Correspondence Address: Csanádi, M.; Doctoral School of Pharmacological and Pharmaceutical Sciences, Honvéd u. 3, Hungary; email: marcell.csanadi@syreon.eu AB - Health technology assessment (HTA) is not simply a mechanistic technical exercise as it takes place within a specific institutional context. Yet, we know little about how this context influences the operation of HTA and its ability to influence policy and practice. We seek to demonstrate the importance of considering institutional context, using a case study of Hungary, a country that has pioneered HTA in Central and Eastern Europe. We conducted 26 in-depth, semi-structured interviews with public- and private-sector stakeholders. We found that while the HTA Department, the Hungarian HTA organisation, fulfilled its formal role envisaged in the legislation, its potential for supporting evidence-based decision-making was not fully realised given the low levels of transparency and stakeholder engagement. Further, the Department's practical influence throughout the reimbursement process was perceived as being constrained by the payer and policy-makers, as well as its own limited organisational capacity. There was also scepticism as to whether the current operational form of the HTA process delivered 'good value for money'. Nevertheless, it still had a positive impact on the development of a broader institutional HTA infrastructure in Hungary. Our findings highlight the importance of considering institutional context in analysing the HTA function within health systems. LA - English DB - MTMT ER - TY - JOUR AU - Danku, Nóra AU - Fekete, Rita AU - Fekete, Sándor AU - Boncz, Imre TI - A DADA drogprevenciós program hatékonyságvizsgálata hetedik évfolyamos általános iskolai tanulók körében JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 PY - 2019 IS - 23 SP - 914 EP - 920 PG - 7 SN - 0030-6002 DO - 10.1556/650.2019.31417 UR - https://m2.mtmt.hu/api/publication/30705563 ID - 30705563 AB - Introduction: Drug-taking habit is not infrequent in the young population. There is a need of proven effective drug prevention programs. Aim: The aim of our study was to analyze the efficiency of the Hungarian Police's DADA school-drug prevention program. Method: The research program was carried out by a standard questionnaire at Apáczai Csere János Primary School in Pécs and Kodolányi János Primary School in Pécsvárad. Results: After analyzing the participating students' answers, the results showed that the rate of those, who "know everything" about drugs, increased from 27% to 37.3%, and of those, who did "not know anything", decreased from 5.6% to 1.6% (p<0.001). Regarding self-efficiency, the DADA program did not show any significant change (p = 0.364). However, less than 60% of the students agreed the statements: "I have learned a lot from the trainings" and "I received answers to several questions that I had been interested in earlier." Conclusion: We can conclude that the DADA program was successful. Regarding the chosen reactions and opinions about the program, we have to consider the sociocultural background of the participants. Orv Hetil. 2019; 160(23): 914-920. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Dózsa, Csaba AU - Jankus, Katalin AU - Mariann Helter, Tímea TI - Structural Changes in the Hungarian Healthcare System Between 2000 and 2017 JF - VALUE IN HEALTH REGIONAL ISSUES J2 - VAL HEALTH REG ISS VL - 19 PY - 2019 SP - 92 EP - 98 PG - 7 SN - 2212-1099 DO - 10.1016/j.vhri.2019.05.002 UR - https://m2.mtmt.hu/api/publication/30756588 ID - 30756588 LA - English DB - MTMT ER - TY - JOUR AU - Eisingerné Balassa, Boglárka AU - Csákvári, Tímea AU - Ágoston, István TI - Az egészségbiztosítási gyógyszerkiadások alakulása Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 PY - 2019 IS - Supplement 1 SP - 49 EP - 54 PG - 6 SN - 0030-6002 DO - 10.1556/650.2019.31394 UR - https://m2.mtmt.hu/api/publication/30425727 ID - 30425727 N1 - Széchenyi István Egyetem, Kautz Gyula Gazdaságtudományi Kar, Győr, Hungary Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Pécs, Hungary Cited By :1 Export Date: 10 May 2019 CODEN: ORHEA Correspondence Address: Boglárka, E.B.; Széchenyi István Egyetem, Kautz Gyula Gazdaságtudományi KarHungary; email: eisingerne@sze.hu Széchenyi István Egyetem, Kautz Gyula Gazdaságtudományi Kar, Győr, Hungary Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Pécs, Hungary Cited By :1 Export Date: 13 September 2019 CODEN: ORHEA Correspondence Address: Boglárka, E.B.; Széchenyi István Egyetem, Kautz Gyula Gazdaságtudományi KarHungary; email: eisingerne@sze.hu AB - Introduction: In Hungary, health expenditures -especially the question of health insurance subsidies for medicinal products -are becoming increasingly important. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Ghabri, Salah AU - Josselin, Jean-Michel AU - Le Maux, Benoit TI - Could or Should We Use MCDA in the French HTA Process? JF - PHARMACOECONOMICS J2 - PHARMACOECONOMICS VL - 37 PY - 2019 IS - 12 SP - 1417 EP - 1419 PG - 3 SN - 1170-7690 DO - 10.1007/s40273-019-00846-w UR - https://m2.mtmt.hu/api/publication/30872719 ID - 30872719 N1 - Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorité de Santé, HAS), 5 Avenue du Stade de France, Saint-Denis La Plaine Cedex, 93218, France Faculty of Economics, University of Rennes 1, CREM-CNRS, Place Hoche 7, Rennes cedex, 35065, France Cited By :3 Export Date: 9 May 2023 CODEN: PARME Correspondence Address: Ghabri, S.; Department of Economic and Public Health Evaluation, 5 Avenue du Stade de France, France; email: s.ghabri@has-sante.fr LA - English DB - MTMT ER - TY - JOUR AU - Gupta, Vipin AU - Sachdeva, Mohinder P. AU - Walia, Gagandeep Kaur TI - “Mendelian Randomization” Approach in Economic Assessment of Health Conditions JF - FRONTIERS IN PUBLIC HEALTH J2 - FRONT PUBLIC HEALTH VL - 7 PY - 2019 PG - 8 SN - 2296-2565 DO - 10.3389/fpubh.2019.00002 UR - https://m2.mtmt.hu/api/publication/30425471 ID - 30425471 N1 - Department of Anthropology, University of Delhi, New Delhi, India Public Health Foundation of India, Gurugram, India Export Date: 13 May 2019 Correspondence Address: Gupta, V.; Department of Anthropology, University of DelhiIndia; email: udaiig@gmail.com Department of Anthropology, University of Delhi, New Delhi, India Public Health Foundation of India, Gurugram, India Export Date: 13 September 2019 Correspondence Address: Gupta, V.; Department of Anthropology, University of DelhiIndia; email: udaiig@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Hornyák, Lajos AU - Nagy, Zsolt AU - Ilku, Lívia AU - Tálos, Zsuzsanna AU - Endrei, Dóra AU - Ágoston, István AU - Csákvári, Tímea AU - Danku, Nóra AU - Répásy, Balázs AU - Boncz, Imre TI - Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary. JF - EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH J2 - EXPERT REV PHARMACOECON OUTCOMES RES VL - 19 ET - 0 PY - 2019 IS - 6 SP - 725 EP - 731 PG - 7 SN - 1473-7167 DO - 10.1080/14737167.2019.1582334 UR - https://m2.mtmt.hu/api/publication/30436457 ID - 30436457 AB - After patent expiration of original biological drugs, they can be marketed as biosimilars. In this study, we analyzed the bid approach of the Hungarian National Health Insurance Fund Administration (NHIFA) based on the results of two consecutive bids on colony stimulating factor (CSF).The Hungarian NHIFA database was used to analyze the changes in the number of patients treated with CSF and reimbursement paid by NHIFA, 12 months preceding and following the bids.13974 patients received granulocyte-CSF treatment during 12 months prior to bidding. A 4.5% decrease (13352) and further 1.3% decrease (13185) in the total number of patients were observed during the first and second years, respectively. The annual health insurance subsidy paid during 12 months prior to the bids was. 7.49 billion Hungarian Forint (HUF) or 26.8 million Euro (EUR). In the first year following the bid we found a 3.3 billion HUF (12.4 million EUR) decrease in health insurance subsidy (44% reduction). A further 7.9 % reduction was observed during the second year, resulting in an annual health insurance subsidy of 3.59 billion HUF (12.1 million EUR).During the 2 years bid (public procurement procedure), the National Health Insurance Fund Administration managed to reduce the health insurance subsidy paid for the reimbursement of both original and biosimilar G-CSF products by 3.89 billion HUF (14.7 million EUR) or 51.9 % without significant changes in the number of patients having access to treatment. LA - English DB - MTMT ER - TY - JOUR AU - Szombati, Ivett TI - Social services in the social security system of family support JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 PY - 2019 IS - 1 SP - 43 EP - 48 PG - 6 SN - 0030-6002 DO - 10.1556/650.2019.31395 UR - https://m2.mtmt.hu/api/publication/30596465 ID - 30596465 N1 - Cited By :1 Export Date: 10 May 2019 CODEN: ORHEA Correspondence Address: Ivett, S.; Széchenyi István Egyetem, Egészség- és Sporttudományi Kar, Egészségtudományi TanszékHungary; email: szombatiyvett@gmail.com Cited By :1 Export Date: 13 May 2019 CODEN: ORHEA Correspondence Address: Ivett, S.; Széchenyi István Egyetem, Egészség- és Sporttudományi Kar, Egészségtudományi TanszékHungary; email: szombatiyvett@gmail.com Cited By :1 Export Date: 13 September 2019 CODEN: ORHEA Correspondence Address: Ivett, S.; Széchenyi István Egyetem, Egészség- és Sporttudományi Kar, Egészségtudományi TanszékHungary; email: szombatiyvett@gmail.com AB - Introduction and aim: In my study, analysing the data available from the change of the regime to the present day, from among the social services, I examine the changes of the financial support relating to children and its parts which are currently financed from the budget of the National Health Insurance Fund of Hungary, with special emphasis on the Child Care Benefit and the Child Care Allowance and their modifications. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kovács, Gábor TI - A rokkantság, megváltozott munkaképesség, rehabilitációs ellátások változása Magyarországon 1990 és 2015 között JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 PY - 2019 IS - Supplement 1 SP - 29 EP - 36 PG - 8 SN - 0030-6002 DO - 10.1556/650.2019.31372 UR - https://m2.mtmt.hu/api/publication/30425412 ID - 30425412 AB - Bevezetés: A megváltozott munkaképességű személyek részére kifizetett és jelenleg az Egészségbiztosítási Alap költségvetésének közel 30%-át kitevő pénzbeli ellátásokra való jogosultság megállapítása, a keret racionális felhasználása régóta komoly problémákat vet fel. Célkitűzés: A tanulmány célja az elmúlt 25 év statisztikai adatainak és a jogszabályi környezet változásának az összehasonlító vizsgálata. Módszerek: Vizsgálatainkat az Országos Egészségbiztosítási Pénztár, a Központi Statisztikai Hivatal adatsoraira, valamint az Állami Számvevőszék, továbbá a Nemzetgazdasági Minisztérium államháztartási jelentéseire alapoztuk. A vizsgált időszakra vonatkozóan elemeztük a megváltozott munkaképességű személyek számára kifizetett pénzbeli ellátások mértékét, az azok csökkentésére tett intézkedéseket, illetve az alapul fekvő jogszabályi háttér változását. Hosszmetszetben vizsgáltuk a háttérben húzódó komplex társadalmi, szociológiai folyamatainak vonatkozó dimenziót, továbbá a megváltozott munkaképesség orvosszakmai értékelésének rendszerét, illetve a komplex rehabilitációs ellátások megjelenését, hatásait. Eredmények: Az elmúlt 25 évben az eltérő megnevezés alatt (rokkantság, munkaképesség-csökkenés, egészségkárosodás, rehabilitációs ellátás) kifizetett pénzbeli ellátások (járadék, nyugellátás) az Egészségbiztosítási Alap költségvetésének még ma is meghatározó részét képezik (2016-ban 315 milliárd forint). Komoly erőfeszítések történtek arra, hogy a régebben alapvetően automatikusan folyósított rokkantsági nyugdíj és járadék rendszerét a megmaradt egészségi állapotra építő, azt megtartó, javító komplex orvosi, foglalkozási és szociális rehabilitációval váltsák fel. Az intézkedések célja alapvetően a költségvetés kiadásainak csökkentése, illetve a kifizetett összeg rehabilitációs ellátásokra építő eredményesebb hasznosulása. Következtetés: A vizsgált hosszú időperiódusban lezajló társadalmi, szociológiai változások sajnálatosan elősegítették a rokkantsági ellátást igénybe vevők számának kezdetben gyors emelkedését, majd magas szinten stabilizálódását és a költségvetés jelentős terhelését. Ezt a pénzbeni ellátás rehabilitációs szemléletű átalakítása sem volt képes kellően ellensúlyozni. Introduction: In our study, based on the data of the last 25 years, we analyzed the changes in the cash benefits paid to people with reduced working capacity, currently accounting for nearly 30% of the budget of the National Health Insurance Fund of Hungary. Aim: The purpose of our study is to compare the statistical data of the past 25 years and the changes in the legal environment. Methods: Our research was based on the data series of the National Health Insurance Fund of Hungary and the Hungarian Central Statistical Office as well as on the public finance reports of the State Audit Office of Hungary and the Ministry for National Economy. For the period under review, we analyzed the extent of the cash benefits paid to people with reduced working capacity, the measures taken to reduce these benefits, and the related legal background. In the long term, we examined the relevant dimension of the complex sociological processes in the background as well as the medical evaluation of the changed working ability. Results: In the last 25 years, benefits (annuity, retirement) paid under different denominations (disability, work ability reduction, health impairment, rehabilitation benefit) are still a decisive part of the health insurance budget (HUF 315 billion in 2016). Serious efforts have been made to replace the previously funded system of invalidity pension and annuity system, with the complex medical, occupational, and social rehabilitation, maintenance and improvement of the remaining state of health. The purpose of the measures is essentially to reduce budget expenditures and to improve the utilization of the amount paid on rehabilitation benefits. Conclusion: The sociological changes that occurred during the long period of time regrettably helped to initially increase the number of recipients of invalidity benefits, to stabilize them at a high level and to have a significant burden on the budget. This could not be counterbalanced by the rehabilitation approach of money supply either. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Nogel, Mónika TI - Az Egészségbiztosítási Alap táppénzes trendjei Magyarországon 1997 és 2017 között JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 ET - 0 PY - 2019 IS - Suppl. 1 SP - 37 EP - 42 PG - 6 SN - 0030-6002 DO - 10.1556/650.2019.31391 UR - https://m2.mtmt.hu/api/publication/30397037 ID - 30397037 AB - Introduction: The role of sick-pay is to compensate for loss of wage in case of incapacity for work, to ensure that there will be no break in the existential state of the incapacitated person.Aim: The purpose of our research was to examine data on sickness benefit and payroll data for the period 1997-2017.Data and methods: Our research was based on the data of the National Health Insurance Fund of Hungary, the Hungarian Central Statistical Office, the State Audit Office of Hungary and the Hungarian State Treasury as well as on the background reports of the European Commission's Social Protection Committee and the Organisation for Economic Co-operation and Development (OECD), and it is based on the legal environment of sick-pay.Results: In 1997, there were 119 000 of 3.558 million, in 1998 114 000 of 3.530 million, in 1999 115 000 of 3.433 million, in 2000 112 000 of 3.465 million, in 2006 100 000 of 3.523 million, in 2012 55 000 of 3.769 million entitled people on sick leave on average per day. In 2017, the number of entitled persons increased to 4.018 million, while the average number of sick days per day was 70 000. According to data from gender and age-based analysis, in most cases, women with childbearing were on sick-leave, the proportion of males was higher in relation to industrial accident. Between 2014 and 2016, the proportion of women on sick leave per day was 59-60%, while the major reason for sick-pay among men was the industrial accident. The distribution by age did not change significantly. In 2014-2015, the age-group 30-34, while in 2016 the age-group 35-39 had the highest utilization of sick-pay.Conclusion: We can conclude that the use of sick-pay is affected by the employment rate, legal changes affecting the amount of sick-pay and social trends like substitution difficulties due to labor shortages and fear of losing jobs. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Oliveira, M.D. AU - Mataloto, I. AU - Kanavos, P. TI - Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art JF - EUROPEAN JOURNAL OF HEALTH ECONOMICS J2 - EUR J HEALTH ECON VL - 20 PY - 2019 IS - 6 SP - 891 EP - 918 PG - 28 SN - 1618-7598 DO - 10.1007/s10198-019-01052-3 UR - https://m2.mtmt.hu/api/publication/30678552 ID - 30678552 N1 - Funding Agency and Grant Number: European Commission [779312] Funding text: Partial financial support for Monica Oliveira's work in this study was provided by a grant from the European Commission, DG Research under the auspices of the IMPACT-HTA H2020 project (grant agreement number: 779312). The views represented in the paper do not necessarily reflect the views of the European Commission. We thank Carlos Bana e Costa, Ana Vieira and Aris Angelis for insightful discussions in earlier drafts of the paper; we are grateful to two anonymous referees for comments and suggestions which helped us improve the paper. All outstanding errors are our own. LA - English DB - MTMT ER - TY - JOUR AU - Pónusz, Róbert AU - Endrei, Dóra AU - Kovács, D AU - Németh, Noémi AU - Schiszler, Bence AU - Molics, Bálint AU - Raposa, Bence AU - Gulácsi, László AU - Gamal Eldin, Mohamed AU - Boncz, Imre TI - Az egynapos sebészeti ellátás igénybevételi mutatóinak elemzése Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 PY - 2019 IS - 17 SP - 670 EP - 678 PG - 9 SN - 0030-6002 DO - 10.1556/650.2019.31342 UR - https://m2.mtmt.hu/api/publication/30642103 ID - 30642103 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Reddy, Brian P. AU - Walters, Stephen J. AU - Duenas, Alejandra AU - Thokala, Praveen AU - Kelly, Michael P. TI - A role for MCDA to navigate the trade-offs in the National Institute for Health and Care Excellence's public health recommendations JF - OPERATIONS RESEARCH FOR HEALTH CARE J2 - OPERATIONS RESEARCH FOR HEALTH CARE VL - 23 PY - 2019 PG - 9 SN - 2211-6923 DO - 10.1016/j.orhc.2019.02.001 UR - https://m2.mtmt.hu/api/publication/31083266 ID - 31083266 AB - Recommendations made by the UK's National Institute for Health and Care Excellence (NICE) consider a range of relevant factors. Most famously, this includes interventions' incremental cost-effectiveness ratios (ICER). Given the ICER's primacy in such decision-making, it is sometimes assumed as almost analogous to an optimisation problem, maximising the number of Quality Adjusted Life Years generated by the health system subject to costs. However, structured OR techniques could still prove beneficial in informing the broader decision-making problem. Decisions are currently arrived at by advisory committees through a combination of structured processes and relatively unstructured deliberations. In principle, decision makers are expected to consider dozens of relevant factors after the completion of the economic modelling stage. No model is currently used to combine these, and MCDA may be suitable to better structure and aid these discussions and to highlight the opportunity costs associated with them. This paper outlines some of the factors currently considered in public health settings, proposes a number of approaches as to how MCDA-inspired techniques could be grafted onto current NICE processes incrementally, and considers the appropriateness of their use in this setting given NICE's role in the health system. The paper focuses on the formulation of NICE's public health guidance, as this area has a specific focus on equity and the determinants of health, and is therefore has the most obvious need to balance ICERs and other factors. (C) 2019 Elsevier Ltd. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Varga, Veronika AU - Boncz, Imre AU - Sebestyén, Andor AU - Endrei, Dóra AU - Ágoston, István AU - Péter, Iván AU - Molics, Bálint TI - A gyógyfürdőellátások igénybevételi mutatói Magyarországon JF - ORVOSI HETILAP J2 - ORV HETIL VL - 160 ET - 0 PY - 2019 IS - Suppl. 1 SP - 22 EP - 28 PG - 7 SN - 0030-6002 DO - 10.1556/650.2019.31373 UR - https://m2.mtmt.hu/api/publication/30425413 ID - 30425413 N1 - Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Pécs, Hungary Zsigmondy Vilmos Harkányi Gyógyfürdőkórház, Harkány, Hungary Pécsi Tudományegyetem, Egészségtudományi Kar, Fizioterápiás és Sporttudományi Intézet, Pécs, Hungary Cited By :7 Export Date: 18 January 2024 CODEN: ORHEA Correspondence Address: Molics, B.; Pécsi Tudományegyetem, Hungary; email: molics.balint@etk.pte.hu AB - Introduction: The role of spa therapy is well defined and its importance has significantly increased in the healthcare but the utilization indicators of the implemented treatments are less known.Aim: The objective of our study was to analyze the utilization and the social insurance indicators of the healthcare publicly financed by health insurance in spa institutions.Data and methods: The data used for the analysis were derived from the funding database of the National Health Insurance Fund of Hungary. The period examined covered the years between 2009 and 2016. The spa treatment counts, social insurance expenses, the territorial inequalities in utilization, sex and age distribution of the treatments were examined.Results: The treatment counts were the highest (7 349 587) in 2009 and they gradually decreased with 6 558 204 treatments by 2012. 'Spa pool of medicinal water' treatment was the most common care in each year which incidence showed a downward trend during the past years: 2 544 617 treatments were performed in 2009 but 2016 showed only 1 898 338 treatments. We found the highest health insurance expenditures in 2016: 4.261 billion HUF or 13.8 EUR. In the previous years, there was a lower health insurance expenditure: in 2010 3.928 billion HUF (14.3 million EUR), in 2011 3.921 billion HUF (14.0 million EUR) and in 2012 3.875 billion HUF (13.4 million EUR). The utilization made the highest incidence of treatments in Csongrad county with 13 17 4 / 1 0 000 inhabitants and 8160 thousand HUF/10 000 inhabitants of social security subsidy in 2016. The lowest utilization counts for treatments were found in Nograd county with 3233/10 000 inhabitants and 2192 thousand HUF/10 000 inhabitants of social security subsidy. The highest utilization indicators were found in the age group between 60 and 69 in the distribution of population and genders.Conclusion: In the utilization of spa therapy funded by health insurance fund, no significant change has occurred during the past years but territorial discrepancies can be seen in sex, age, and county breakdown. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Baran-Kooiker, Aleksandra AU - Czech, Marcin AU - Kooiker, Coen TI - Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development? JF - FRONTIERS IN PUBLIC HEALTH J2 - FRONT PUBLIC HEALTH VL - 6 PY - 2018 PG - 24 SN - 2296-2565 DO - 10.3389/fpubh.2018.00287 UR - https://m2.mtmt.hu/api/publication/30497110 ID - 30497110 N1 - Department of Pharmacoeconomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland Department of Pharmacoeconomics, The Institute of Mother and Child, Warsaw, Poland Warsaw University of Technology Business School, Warsaw, Poland Warsaw, Poland Cited By :32 Export Date: 9 May 2023 Correspondence Address: Baran-Kooiker, A.; Department of Pharmacoeconomics, Poland; email: aleksandra.baran@gmail.com Correspondence Address: Czech, M.; Department of Pharmacoeconomics, Poland; email: marcin.czech@imid.med.pl AB - Background: Multi-criteria decision analysis (MCDA) is a decision-making tool that can take into account multidimensional factors and enables comparison of (medical) technologies by combining individual criteria into one overall appraisal. The MCDA approach has slowly gained traction within Health Technology Assessment (HTA) and its elements are gradually being incorporated into HTA across Europe. Several groups of scientists have proposed MCDA approaches targeted toward orphan drugs and rare diseases by including criteria specific to rare diseases. The goal of this article is to provide an overview of the current state of knowledge and latest developments in the field of MCDA in HTA for orphan drugs, to review existing models, their design characteristics, as well as to identify opportunities for further model improvement. LA - English DB - MTMT ER - TY - JOUR AU - Bertalan, N. TI - Megjelent Dr. Purebl György könyve: alacsony intenzitású pszichológiai intervenciók a mindennapi orvosi gyakorlatban JF - LEGE ARTIS MEDICINAE J2 - LEGE ART MED VL - 28 PY - 2018 IS - 6-7 SP - 271 EP - 274 PG - 4 SN - 0866-4811 UR - https://m2.mtmt.hu/api/publication/30671341 ID - 30671341 N1 - Export Date: 10 May 2019 CODEN: LAMEF Correspondence Address: Bertalan, N.; Magyar Egészség-gazdaságtani Társaság ElnökeHungary Export Date: 11 February 2020 CODEN: LAMEF Correspondence Address: Bertalan, N.; Magyar Egészség-gazdaságtani Társaság ElnökeHungary Export Date: 12 February 2020 CODEN: LAMEF Correspondence Address: Bertalan, N.; Magyar Egészség-gazdaságtani Társaság ElnökeHungary Export Date: 9 September 2020 CODEN: LAMEF Correspondence Address: Bertalan, N.; Magyar Egészség-gazdaságtani Társaság ElnökeHungary LA - Hungarian DB - MTMT ER - TY - JOUR AU - Danku, Nóra AU - Kerner, Ágnes AU - Elmer, Diána AU - Németh, Noémi AU - Boncz, Imre TI - A drogepidemiológia és drogprevenció aktuális helyzete szakirodalmi áttekintés keretében. Fókuszban Magyarország TS - Fókuszban Magyarország JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 9 PY - 2018 IS - 2 SP - 63 EP - 72 PG - 10 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/31142482 ID - 31142482 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Juhász, Krisztina AU - Boncz, Imre AU - Kanizsai, Péter László AU - Sebestyén, Andor TI - Az ellenoldali csípőtáji törésig eltelt időt befolyásoló prognosztikai tényezők vizsgálata JF - ORVOSI HETILAP J2 - ORV HETIL VL - 159 ET - 0 PY - 2018 IS - 38 SP - 1543 EP - 1547 PG - 5 SN - 0030-6002 DO - 10.1556/650.2018.31179 UR - https://m2.mtmt.hu/api/publication/3419368 ID - 3419368 N1 - Cited By :4 Export Date: 2 October 2023 CODEN: ORHEA Correspondence Address: Kanizsai, P.; Semmelweis Egyetem, Szabadság út 7, Hungary; email: krisztina.juhasz01@gmail.com) AB - Abstract: Introduction: Although several national studies reported on the risk factors for contralateral hip fracture, there are no data about the prognostic factors of the time until contralateral hip fractures. Aim: The aim of the study was to analyse the impact of different prognostic factors on the time until the development of contralateral fracture and to determine the incidence of contralateral hip fractures after femoral neck fractures. Method: Patients aged 60 years and over with contralateral hip fracture between 01 Jan 2000 and 31 Dec 2008 were identified among those who suffered their femoral neck fracture in Hungary in 2000. Risk factors as age, sex, comorbidities, type of fracture and surgery, place of living and hospitals providing treatment for primary fracture were analysed by one way ANOVA focusing on the time until the development of contralateral hip fracture. Results: 312 patients met the inclusion criteria. The incidence of contralateral hip fracture after femoral neck fracture ranged between 1.5% and 2.1%, the cumulative incidence was 8.24%. The mean time until the development of contralateral hip fracture was 1159.8 days. The incidence of contralateral hip fracture showed no significant deviation. Significantly shorter time (p = 0.010) was detected until the contralateral hip fracture in older patients with femoral neck fracture. Conclusions: The yearly incidence of contralateral hip fracture showed no significant difference by patients with femoral neck fracture over 60 years. The shorter time until the contralateral hip fracture by the older age groups highlights the need of elaboration of prevention strategies. Orv Hetil. 2018; 159(38): 1543?1547. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Marsh, Kevin AU - Thokala, Praveen AU - Youngkong, Sitaporn AU - Chalkidou, Kalipso TI - Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings JF - Cost Effectiveness and Resource Allocation J2 - COST EFFECT RESOUR A VL - 16 PY - 2018 PG - 9 SN - 1478-7547 DO - 10.1186/s12962-018-0125-8 UR - https://m2.mtmt.hu/api/publication/30575464 ID - 30575464 N1 - Funding Agency and Grant Number: Brinson Foundation; Payne Family Foundation; MRC [MR/R015600/1] Funding Source: UKRI Funding text: The publication costs for this article were funded by Mark O'Friel, the Brinson Foundation, and the Payne Family Foundation. Supplement: 1 AB - BackgroundMulticriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of MCDA for HTA, with a particular focus on lower and middle-income countries (LMICs), and to highlight potential solutions to these challenges.Methodological challengesKey lessons from existing applications of MCDA to HTA are summarized, including: that the socio-technical design of the MCDA reflect the local decision problem; the criteria set properties of additive models are understood and applied; and the alternative approaches for estimating opportunity cost, and the challenges with these approaches are understood.Practical challengesExisting efforts to implement HTA in LMICs suggest a number of lessons that can help overcome the practical challenges facing the implementation of MCDA in LMICs, including: adapting inputs from other settings and from expert opinion; investing in technical capacity; embedding the MCDA in the decision-making process; and ensuring that the MCDA design reflects local cultural and social factors.ConclusionMCDA has the potential to improve decision making in LMICs. For this potential to be achieved, it is important that the lessons from existing applications of MCDA are learned. LA - English DB - MTMT ER - TY - JOUR AU - Marsh, Kevin D AU - Sculpher, Mark AU - Caro, J Jaime AU - Tervonen, Tommi TI - The Use of MCDA in HTA: Great Potential, but More Effort Needed JF - VALUE IN HEALTH J2 - VALUE HEALTH VL - 21 PY - 2018 IS - 4 SP - 394 EP - 397 PG - 4 SN - 1098-3015 DO - 10.1016/j.jval.2017.10.001 UR - https://m2.mtmt.hu/api/publication/27574478 ID - 27574478 N1 - Cited By :59 Export Date: 9 May 2023 CODEN: VIHLF Correspondence Address: Marsh, K.D.Metro Building, 6th Floor, 1 Butterwick, United Kingdom; email: kevin.marsh@evidera.com LA - English DB - MTMT ER - TY - JOUR AU - Répásy, Balázs AU - Endrei, Dóra AU - Zemplényi, Antal Tamás AU - Ágoston, István AU - Boncz, Imre TI - A montelukasztterápia betegterheinek változása a generikus árverseny hatására JF - ORVOSI HETILAP J2 - ORV HETIL VL - 159 PY - 2018 IS - 17 SP - 682 EP - 687 PG - 6 SN - 0030-6002 DO - 10.1556/650.2018.31020 UR - https://m2.mtmt.hu/api/publication/3369491 ID - 3369491 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Zozaya, Neboa AU - Martinez-Galdeano, Lucia AU - Alcala, Bleric AU - Carlos, Armario-Hita Jose AU - Carmona, Concepcion AU - Manuel, Carrascosa Jose AU - Herranz, Pedro AU - Jesus, Lamas Maria AU - Trapero-Bertran, Marta AU - Hidalgo-Vega, Alvaro TI - Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis JF - BIODRUGS J2 - BIODRUGS VL - 32 PY - 2018 IS - 3 SP - 281 EP - 291 PG - 11 SN - 1173-8804 DO - 10.1007/s40259-018-0284-3 UR - https://m2.mtmt.hu/api/publication/27601998 ID - 27601998 N1 - \n Department of Health Economics, Weber Economía y Salud, c/Norias 123, Majadahonda, Madrid, 28221, Spain \n Department of Dermatology, University Hospital of Puerto Real, Puerto Real, Cádiz, Spain \n Department of Healthcare, Servicio Extremeño de Salud, Mérida, Badajoz, Spain \n Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain \n Department of Dermatology, La Paz Universitary Hospital-Carlos III, Madrid, Spain \n Servicio de Farmacia, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain \n Faculty of Economics and Social Sciences, Universitat Internacional de Catalunya, Barcelona, Spain \n Fundación Weber, Majadahonda, Madrid, Spain \n Universidad de Castilla-La Mancha, Campus de Toledo, Toledo, Spain \n Export Date: 21 November 2018 \n CODEN: BIDRF \n Correspondence Address: Zozaya, N.; Department of Health Economics, Weber Economía y Salud, c/Norias 123, Majadahonda, Spain; email: neboa.zozaya@weber.org.es LA - English DB - MTMT ER - TY - JOUR AU - Annemans, Lieven AU - Ayme, Segolene AU - Le Cam, Yann AU - Facey, Karen AU - Gunther, Penilla AU - Nicod, Elena AU - Reni, Michele AU - Roux, Jean-Louis AU - Schlander, Michael AU - Taylor, David AU - Tomino, Carlo AU - Torrent-Farnell, Josep AU - Upadhyaya, Sheela AU - Hutchings, Adam AU - Le Dez, Lugdivine TI - Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) JF - ORPHANET JOURNAL OF RARE DISEASES J2 - ORPHANET J RARE DIS VL - 12 PY - 2017 PG - 15 SN - 1750-1172 DO - 10.1186/s13023-017-0601-9 UR - https://m2.mtmt.hu/api/publication/26584338 ID - 26584338 N1 - Funding Agency and Grant Number: EUCOPE; Celgene Corporation Funding text: Members of the Working Group participated on a voluntary basis and did not receive payment, other than reimbursement of travel expenses where necessary. Secretariat services and medical writing support were provided to the group funded jointly by EUCOPE and Celgene Corporation. LA - English DB - MTMT ER - TY - JOUR AU - Brixner, Diana AU - Maniadakis, Nikos AU - Kaló, Zoltán AU - Hu, Shanlian AU - Shen, Jie AU - Wijaya, Kalman TI - Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets JF - VALUE IN HEALTH REGIONAL ISSUES J2 - VAL HEALTH REG ISS VL - 13 PY - 2017 SP - 1 EP - 6 PG - 6 SN - 2212-1099 DO - 10.1016/j.vhri.2017.02.001 UR - https://m2.mtmt.hu/api/publication/3222103 ID - 3222103 AB - Off-patent pharmaceuticals (OPPs) represent more than 60% of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population?s health. In addition, many health care systems lack the resources or expertise to evaluate such products, and current assessment methods can be complex and difficult to adapt to a health system?s needs. Multicriteria decision analysis (MCDA) simple scoring is an evidence-based health technology assessment methodology for evaluating OPPs, especially in emerging countries in which resources are limited but decision makers still must balance affordability with factors such as drug safety, level interchangeability, manufacturing site and active pharmaceutical ingredient quality, supply track record, and real-life outcomes. MCDA simple scoring can be applied to pharmaceutical pricing, reimbursement, formulary listing, and drug procurement. In November 2015, a workshop was held at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Milan to refine and prioritize criteria that can be used in MCDA simple scoring for OPPs, resulting in an example MCDA process and 22 prioritized criteria that health care systems in emerging countries can easily adapt to their own decision-making processes. LA - English DB - MTMT ER - TY - JOUR AU - Drake, JI AU - de Hart, JCT AU - Monleón, C AU - Toro, W AU - Valentim, J TI - Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016 JF - JOURNAL OF MARKET ACCESS & HEALTH POLICY J2 - JMAHP VL - 5 PY - 2017 IS - 1 PG - 10 SN - 2001-6689 DO - 10.1080/20016689.2017.1360545 UR - https://m2.mtmt.hu/api/publication/27004918 ID - 27004918 N1 - Export Date: 07 December 2023; Correspondence Address: J.C.T. de Hart; FIFARMA, Bogotá, D.C, Colombia; email: jctrujillo@fifarma.org LA - English DB - MTMT ER - TY - JOUR AU - Gilabert-Perramon, Antoni AU - Torrent-Farnell, Josep AU - Catalan, Arancha AU - Prat, Alba AU - Fontanet, Manel AU - Puig-Peiro, Ruth AU - Merino-Montero, Sandra AU - Khoury, Hanane AU - Goetghebeur, Mireille M AU - Badia, Xavier TI - DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS JF - INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE J2 - INT J TECHNOL ASSESS VL - 33 PY - 2017 IS - 1 SP - 111 EP - 120 PG - 10 SN - 0266-4623 DO - 10.1017/S0266462317000149 UR - https://m2.mtmt.hu/api/publication/26768767 ID - 26768767 N1 - Funding Agency and Grant Number: Bristol-Myers Squibb Funding text: We acknowledge the contribution of all the PASFTAC participants and their collaboration in the project. The study has been conducted by Omakase Consulting, with the collaboration of LASER Analytica and the EVIDEM Collaboration. Omakase acknowledges the collaboration of Bristol-Myers Squibb for the sponsorship of the project and manuscript. LA - English DB - MTMT ER - TY - JOUR AU - Inotai, András AU - Csanádi, Marcell AU - Harsányi, András AU - Németh, Bertalan TI - Drug Policy in Central Eastern Europe: Hungary JF - VALUE IN HEALTH REGIONAL ISSUES J2 - VAL HEALTH REG ISS VL - 13 PY - 2017 SP - 16 EP - 22 PG - 7 SN - 2212-1099 DO - 10.1016/j.vhri.2017.06.003 UR - https://m2.mtmt.hu/api/publication/3254312 ID - 3254312 N1 - Cited By :10 Export Date: 30 November 2021 Correspondence Address: Inotai, A.; Syreon Research Institute, Mexikói str. 65/A, Hungary; email: andras.inotai@syreon.eu LA - English DB - MTMT ER - TY - JOUR AU - Kawalec, P AU - Tesar, T AU - Vostalova, L AU - Draganic, P AU - Manova, M AU - Savova, A AU - Petrova, G AU - Rugaja, Z AU - Männik, A AU - Sowada, C AU - Stawowczyk, E AU - Harsányi, András AU - Inotai, András AU - Turcu-Stiolica, A AU - Gulbinovic, J AU - Pilc, A TI - Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 8 PY - 2017 PG - 16 SN - 1663-9812 DO - 10.3389/fphar.2017.00892 UR - https://m2.mtmt.hu/api/publication/3314868 ID - 3314868 LA - English DB - MTMT ER - TY - JOUR AU - Marada, Gyula AU - Nagy, Ákos Károly AU - Sebestyén, Andor AU - Zemplényi, Antal Tamás AU - Radnai, Márta AU - Boncz, Imre TI - Az arc-, állcsont-szájsebészeti aktív fekvőbetegosztályok teljesítménymutatói [Performance indicators of maxillofacial surgery inpatient departments] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 158 PY - 2017 IS - 12 SP - 447 EP - 453 PG - 7 SN - 0030-6002 DO - 10.1556/650.2017.30683 UR - https://m2.mtmt.hu/api/publication/3205003 ID - 3205003 AB - INTRODUCTION: In Hungary, the number and structure of the maxillofacial surgery departments underwent significant changes in recent decades. AIM: The aim of our study was to present the actual performance indicators of maxillofacial inpatient departments and based on the available data to compare the departments. METHOD: The study was based on the number of beds founded by the National Health Insurance Fund. Performance data were supplied by the National Health Insurance Fund Administration. The assessment included the following indicators: number of beds institutional breakdown by type, number of reimbursed cases, the weighted case number, hospital stay, bed occupancy rates and average length of stay. RESULTS: In the examined period 40% of active beds (65) were in university hospitals. The distribution of reimbursed cases was similar. The university hospitals showed higher weighted case number and case-mix index. The oral surgery departments' bed occupancy rate (45.75%) was below the national average. CONCLUSION: The indicators show significant differences among different departments in the examined period. Orv. Hetil., 2017, 158(12), 447-453. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Németh, Bertalan AU - Csanádi, Marcell AU - Kaló, Zoltán TI - OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY JF - INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE J2 - INT J TECHNOL ASSESS VL - 33 PY - 2017 IS - 3 SP - 333 EP - 338 PG - 6 SN - 0266-4623 DO - 10.1017/S0266462317000071 UR - https://m2.mtmt.hu/api/publication/3214872 ID - 3214872 AB - Objectives: Our objectives were to assess the current implementation of health technology assessment (HTA) in Hungary and to identify country-specific patterns of challenges and potential improvements. Methods: We applied a structure that can be used to create HTA implementation roadmaps to evaluate various issues regarding HTA implementation. A comprehensive description of the Hungarian HTA system is presented according to relevant literature and experiences of the authors. Results: By investigating eight components of HTA implementation, we identified the most important strengths and weaknesses of the Hungarian system. More specifically, we were mainly focusing on the emergence of HTA capacity, the establishment and current role of Department of HTA, the complex process of decision making, the quality elements developed in the near past, and the activity of Hungarian experts at international collaborations. Conclusions: We concluded that there is a sophisticated methodological and educational basis for HTA in Hungary. A permanent focus on capacity building and changes to the reimbursement procedure can further improve transparency and the scientific basis of decision making in the country. LA - English DB - MTMT ER - TY - JOUR AU - Vajda, Réka AU - Árváné, Egri Cs AU - Kovács, A AU - Budai, A AU - Döbrőssy, L AU - Koiss, R AU - Kívés, Zsuzsanna AU - Boncz, Imre TI - A védőnői méhnyakszűrési pilotprogram minőségi indikátorai és teljesítménymutatói JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 61 PY - 2017 IS - 4 SP - 361 EP - 367 PG - 7 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/3312141 ID - 3312141 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Vajda, Réka AU - Árváné, Egri Cs AU - Kovács, A AU - Budai, A AU - Döbrőssy, L AU - Koiss, R AU - Kívés, Zsuzsanna AU - Boncz, Imre TI - A védőnői méhnyakszűrési pilot program értékelése [Assessment of the pilot program for cervical cancer screening by health visitors] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 158 PY - 2017 IS - 12 SP - 461 EP - 467 PG - 7 SN - 0030-6002 DO - 10.1556/650.2017.30612 UR - https://m2.mtmt.hu/api/publication/3214519 ID - 3214519 N1 - Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet, Mária u. 5-7., Pécs, 7621, Hungary Országos Tisztifoorvosi Hivatal, Budapest, Hungary Egyesített Szent István és Szent László Kórház-Rendelointézet, Szülészeti-Nogyógyászati Osztály, Budapest, Hungary Cited By :5 Export Date: 9 May 2023 CODEN: ORHEA Correspondence Address: Vajda, R.; Pécsi Tudományegyetem, Mária u. 5-7., Hungary; email: reka.vajda@etk.pte.hu LA - Hungarian DB - MTMT ER - TY - JOUR AU - Varga, Veronika AU - Pónusz, Róbert AU - Király, Bence AU - Raposa, Bence AU - Sipos, Dávid AU - Szőts, Bálint AU - Koczka, Viktor TI - Gyógyfürdő ellátások igénybevételi és finanszírozási mutatói Magyarországon JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 8 PY - 2017 IS - 3 SP - 137 EP - 146 PG - 10 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/30439508 ID - 30439508 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Varga, Veronika AU - Raposa, Bence AU - Koczka, Viktor AU - Pónusz, Róbert AU - Kránicz, János AU - Molics, Bálint TI - Túlterhelés okozta panaszok és mozgásszervi sérülések vizsgálata balett táncosoknál JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 8 PY - 2017 IS - 1 SP - 11 EP - 19 PG - 9 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/3376453 ID - 3376453 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Antonanzas, F AU - Terkola, R AU - Postma, M TI - The Value of Medicines: A Crucial but Vague Concept JF - PHARMACOECONOMICS J2 - PHARMACOECONOMICS VL - 34 PY - 2016 IS - 12 SP - 1227 EP - 1239 PG - 13 SN - 1170-7690 DO - 10.1007/s40273-016-0434-8 UR - https://m2.mtmt.hu/api/publication/26247720 ID - 26247720 N1 - Funding Agency and Grant Number: Novartis Pharma, Basel, under the AGORA initiative (a European Think Tank that aims to optimize access for patients to innovative treatments) Funding text: Research and editorial support was funded by Novartis Pharma, Basel, under the AGORA initiative (a European Think Tank that aims to optimize access for patients to innovative treatments). LA - English DB - MTMT ER - TY - JOUR AU - Baji, Petra AU - Garcia-Goni, M AU - Gulácsi, László AU - Mentzakis, E AU - Paolucci, F TI - Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. JF - EUROPEAN JOURNAL OF HEALTH ECONOMICS J2 - EUR J HEALTH ECON VL - 17 PY - 2016 IS - 7 SP - 791 EP - 799 PG - 9 SN - 1618-7598 DO - 10.1007/s10198-015-0721-x UR - https://m2.mtmt.hu/api/publication/2933717 ID - 2933717 N1 - Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., Budapest, 1093, Hungary CERGE-EI, Prague, Czech Republic Departamento de Economía Aplicada II, Universidad Complutense de Madrid, Madrid, Spain Economics Department, School of Social Sciences, University of Southampton, Southampton, United Kingdom University of Bologna, Bologna, Italy Murdoch University, Murdoch, Australia Cited By :8 Export Date: 9 May 2023 CODEN: EJHEA Correspondence Address: Baji, P.; Department of Health Economics, Fővám tér 8., Hungary; email: petra.baji@uni-corvinus.hu AB - BACKGROUND: In addition to cost-effectiveness, national guidelines often include other factors in reimbursement decisions. However, weights attached to these are rarely quantified, thus decisions can depend strongly on decision-maker preferences. OBJECTIVE: To explore the preferences of policymakers and healthcare professionals involved in the decision-making process for different efficiency and equity attributes of interventions and to analyse cross-country differences. METHOD: Discrete choice experiments (DCEs) were carried out in Austria, Hungary, and Norway with policymakers and other professionals working in the health industry (N = 153 respondents). Interventions were described in terms of different efficiency and equity attributes (severity of disease, target age of the population and willingness to subsidise others, potential number of beneficiaries, individual health benefit, and cost-effectiveness). Parameter estimates from the DCE were used to calculate the probability of choosing a healthcare intervention with different characteristics, and to rank different equity and efficiency attributes according to their importance. RESULTS: In all three countries, cost-effectiveness, individual health benefit and severity of the disease were significant and equally important determinants of decisions. All countries show preferences for interventions targeting young and middle aged populations compared to those targeting populations over 60. However, decision-makers in Austria and Hungary show preferences more oriented to efficiency than equity, while those in Norway show equal preferences for equity and efficiency attributes. CONCLUSION: We find that factors other than cost-effectiveness seem to play an equally important role in decision-making. We also find evidence of cross-country differences in the weight of efficiency and equity attributes. LA - English DB - MTMT ER - TY - JOUR AU - Boncz, Imre AU - Sebestyén, Andor TI - Health economics and health insurance aspects of Mendelian randomization JF - AMERICAN JOURNAL OF CLINICAL NUTRITION J2 - AM J CLIN NUTR VL - 104 PY - 2016 IS - 6 SP - 1720 EP - 1720 PG - 1 SN - 0002-9165 DO - 10.3945/ajcn.116.137422 UR - https://m2.mtmt.hu/api/publication/3147586 ID - 3147586 LA - English DB - MTMT ER - TY - JOUR AU - Endrei, Dóra AU - Sebestyén, Andor AU - Gazsó, Gyula Tibor AU - Zemplényi, Antal Tamás AU - Kovács, Gábor AU - Nagy, S AU - Boncz, Imre TI - A szülészeti-nőgyógyászati ellátás finanszírozási kérdései JF - MAGYAR NŐORVOSOK LAPJA J2 - MAGYAR NŐORVOSOK LAPJA VL - 79 PY - 2016 IS - 2 SP - 78 EP - 81 PG - 4 SN - 0025-021X UR - https://m2.mtmt.hu/api/publication/3149799 ID - 3149799 LA - Hungarian DB - MTMT ER - TY - THES AU - Gulácsi, László TI - KRÓNIKUS IMMUNOLÓGIAI BETEGSÉGEK EGÉSZSÉGÜGYI KÖZGAZDASÁGTANI és TECHNOLÓGIAELEMZÉSI VIZSGÁLATA PY - 2016 SP - 187 UR - https://m2.mtmt.hu/api/publication/27457409 ID - 27457409 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Iskrov, G. AU - Kuncheva, R. AU - Stefanov, R. TI - Incorporation of multi-criteria decision analysis into health technology assessment: Experiences and challenges from Bulgaria T2 - Health Economics and Policy Challenges in Global Emerging Markets PB - Nova Science Publishers SN - 9781634847209 PY - 2016 SP - 41 EP - 57 PG - 17 UR - https://m2.mtmt.hu/api/publication/33806394 ID - 33806394 N1 - Cited By :2 Export Date: 9 May 2023 Correspondence Address: Iskrov, G.; Department of Social Medicine and Public Health, Bulgaria; email: iskrov@raredis.org AB - Health technology assessment (HTA) has been used as a guiding instrument to determine if a specific health technology yields more health benefits and value for money than other health technologies that compete for the same limited resources. Multi-criteria decision analysis (MCDA) could play a major role in HTA by offering transparency in coverage decisions. Systematic application of this framework ensures consistency across decisions, allows justification of value judgments, and thus enhances legitimacy of decision-making. MCDA is a structured tool to identify preferred alternatives by means of a combined calculation of the relative importance of different criteria and the performance of the alternatives on these criteria. Selection of criteria is a fundamental step in building an MCDA model, as criteria represent what would be considered important when assessing the value of a health technology. A tentative set of MCDA criteria is recommended to include both equity-specific and efficiency-specific criteria. A comprehensive definition of criteria, weights and scores is crucial, as decision-makers need to apply consistent and coherent interpretation of MCDA inputs and outputs. A major theoretical and practical issue is whether to use a generic MCDA tool in assessing and appraising health technologies, or to adopt specific approaches in different types of health technologies. An important consideration with regard to both approaches - generic and specific - is to include different perspectives in the process of identification of criteria and elicitation of weights and scores. The UK’s National Institute for Health and Care Excellence (NICE) is a highly prominent institution in the field of HTA and reimbursement decision-making. In 2013, NICE overtook the responsibilities of the Advisory Group for National Specialised Services (AGNSS) to appraise high-cost medicinal therapies for ultra-rare conditions. Given the rarity of these disorders, this process is even further from the mainstream than innovative therapies usually are. NICE adopted an interim assessment and appraisal procedure for highly specialist therapies (HST), which resembles very much the standard MCDA process. In this context, while Eastern European countries are often recommended to implement objective and verifiable criteria for reimbursement decisions, the Bulgarian Ordinance on the terms, rules and procedure for regulation and registration of prices for medicinal products successfully tackled this issue. Back in 2011, this piece of legislation was adopted in order to constrain raising drug prices and budgetary burden of medicinal therapies. Among other provisions, the Ordinance improved reimbursement decision-making by adopting an MCDA-based assessment framework. © 2016 by Nova Science Publishers, Inc. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Juhász, Krisztina AU - Boncz, Imre AU - Patczai, Balázs AU - Mintál, Tibor AU - Sebestyén, Andor TI - Risk factors for contralateral hip fractures following femoral neck fractures in elderly: analysis of the Hungarian nationwide health insurance database. JF - EKLEM HASTALIKLAN VE CERRAHISI - JOINT DISEASES AND RELATED SURGERY J2 - EKLEM HAST CERRAHISI VL - 27 PY - 2016 IS - 3 SP - 146 EP - 152 PG - 7 SN - 1305-8282 DO - 10.5606/ehc.2016.30 UR - https://m2.mtmt.hu/api/publication/3148672 ID - 3148672 AB - OBJECTIVES: This study aims to investigate the significance of demographic and clinical factors on incidence of second (contralateral) hip fracture in elderly Hungarian population using the nationwide health insurance database in Hungary. PATIENTS AND METHODS: The study included a total of 3,783 patients (917 males, 2,866 females) treated for primary monotraumatic femoral neck fractures caused by low-energy trauma in the year 2000. Cox regression and Kaplan-Meier survival analyses, and log-rank test were performed to evaluate the following prognostic factors: age, gender, place of living, type of primary fracture and surgical intervention, hospital providing treatment for primary fracture, and comorbidities. RESULTS: A total of 312 patients (8.2%) suffered second hip fractures. The univariate Cox regression analysis showed a significantly higher risk for second hip fracture in patients having advanced age (p=0.001), female gender (p=0.022), living in capital (p=0.024), and having arthroplasty (p=0.001). Advanced age (p